Global In Vitro Diagnostics (IVD) Market Insights, Growth, Share, Size: By Offering, By Application, By Clinical Indication, By End Users, By Sales Channel, By Region & Segmental Forecast, 2023-2031, Comparative Analysis and Trends

  • Industry: Healthcare
  • Report ID: TNR-110-1052
  • Number of Pages: 420
  • Table/Charts : Yes
  • January, 2024
  • Base Year : 2024
  • No. of Companies : 10+
  • No. of Countries : 29
  • Views : 10087
  • Covid Impact Covered: Yes
  • War Impact Covered: Yes
  • Formats : PDF, Excel, PPT

Global In Vitro Diagnostics (IVD) Market was Valued at USD 117.8 Bn in 2022, Growing at an Estimated CAGR of 4% During 2023 – 2031.    

In Vitro Diagnostics (IVD) refers to tests and procedures performed on biological samples (such as blood, urine, tissue) taken from the human body. These tests are conducted outside the body, usually in a laboratory setting, to diagnose diseases, monitor health conditions, and guide treatment decisions. IVD has significantly evolved over time, and its use has become integral to modern healthcare.

The emergence and evolution of in vitro diagnostics (IVD) market has been shaped by centuries of scientific inquiry, technological advancements, and the quest to understand and combat diseases. IVD has become an indispensable part of modern healthcare, aiding in disease diagnosis, monitoring, and personalized treatment approaches.

Global In Vitro Diagnostics (IVD) Market Revenue & Forecast, (US$ Million), 2015 – 2031

The growth of the global in vitro diagnostics (IVD) market has been driven by several key factors. Technological advancements play a crucial role, with companies like Roche Diagnostics innovating automated molecular testing systems such as the cobas platforms, elevating the accuracy and efficiency of diagnostics. The prevalence of chronic diseases like diabetes, cancer, and cardiovascular conditions has fueled the demand for diagnostic tests, prompting companies such as Abbott Laboratories and Siemens Healthineers to develop various tests and platforms tailored to these ailments. Moreover, aging population has led to an increased need for diagnostics targeting age-related diseases, prompting companies like BD and bioMérieux to introduce specialized tests and systems catering to geriatric healthcare needs.

The demand for point-of-care testing (POCT) has surged, prompting companies like Abbott and Quidel to create portable and rapid testing devices that provide immediate results, aligning with the need for quick diagnoses. The COVID-19 pandemic acted as a catalyst, accelerating innovation and demand for diagnostic tests. Companies including Thermo Fisher Scientific, Roche, Abbott, and Qiagen played significant roles in developing and scaling up COVID-19 tests, including PCR and rapid antigen tests, showcasing the industry’s agility and responsiveness in crisis situations.

Advancements in genomics and personalized medicine have led to the development of companion diagnostics, where companies like Foundation Medicine (a Roche company) have crafted tests to identify genetic mutations for targeted cancer therapies. Emerging markets with increasing healthcare expenditure and improving infrastructure have become focal points for growth, prompting companies such as Sysmex Corporation and Ortho Clinical Diagnostics to expand their presence in these regions. Lastly, regulatory changes emphasizing quality standards have pushed companies to invest in research and development, ensuring compliance and obtaining necessary approvals for their diagnostic products. This collective innovation across companies continues to shape and enhance the landscape of diagnostic technologies, addressing evolving healthcare needs on a global scale.

Offerings OutlookSemiautomated systems have significantly contributed for largest market share within the system & instruments category of the in vitro diagnostics (IVD) market. These systems blend human intervention with automated processes, offering a balance between manual and fully automated systems. Their popularity arises from their ability to streamline workflows while retaining some level of user control and flexibility.

In various segments of diagnostics such as clinical chemistry, hematology, and coagulation testing, semiautomated systems have been pivotal. They allow for efficient sample processing, reducing human error while enabling laboratory professionals to oversee and verify results. Companies like Sysmex, Beckman Coulter, and Siemens Healthineers have developed semiautomated systems that provide accuracy, reproducibility, and faster turnaround times. These systems appeal to laboratories of different sizes – from smaller facilities that need some automation to larger labs seeking to complement their fully automated lines. Their adaptability and cost-effectiveness make them a preferred choice for many diagnostic settings. As the industry progresses with a focus on enhancing efficiency and accuracy, semiautomated systems continue to hold a substantial market share in the global in vitro diagnostics (IVD) market due to their ability to strike a balance between manual dexterity and automation in the diagnostic process.

Application OutlookThe dominance of the immunoassay segment in the in vitro diagnostics (IVD) market in 2022 highlights the significance of this diagnostic technique. Immunoassays are crucial in detecting and quantifying specific molecules like hormones, proteins, and antibodies present in biological samples. Their wide application across various medical fields, including infectious diseases, oncology, endocrinology, and autoimmune disorders, contributes to their market dominance. Several factors have propelled the immunoassay segment to the forefront of the vitro diagnostics (IVD) market. The increasing prevalence of chronic and infectious diseases worldwide has led to a growing demand for precise and sensitive diagnostic tools, which immunoassays excel at providing. Companies like Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers have developed advanced immunoassay platforms offering high sensitivity, specificity, and automation, further driving the segment’s dominance.

Clinical Indication Outlook

The infectious diseases segment’s large market share in the in vitro diagnostics (IVD) market is driven by the pressing need for accurate and rapid diagnostic solutions in identifying and managing infectious conditions like HIV, hepatitis, tuberculosis, and emerging pathogens like the SARS-CoV-2 virus responsible for COVID-19. Companies have developed innovative molecular diagnostics, immunoassays, and rapid antigen tests, driving the segment’s prominence.

Regional Outlook North America has historically held a dominant position in the global in vitro diagnostics (IVD) market. The region’s prominence is fueled by various factors, including advanced technological capabilities, substantial healthcare investments, and a competitive landscape of leading companies. The United States and Canada, in particular, have been pivotal in driving innovation and the adoption of sophisticated diagnostic tools. Companies like Abbott Laboratories, Thermo Fisher Scientific, and Roche Diagnostics have established themselves as key players, continuously developing cutting-edge IVD technologies.

Moreover, North America’s significant healthcare spending contributes to the widespread utilization of advanced diagnostics across hospitals, clinics, and research institutions. This financial commitment allows for the incorporation of state-of-the-art IVD solutions into the healthcare system, fostering early disease detection, precision medicine, and improved patient care.

The region’s competitive market environment encourages continuous advancements and the introduction of novel diagnostic solutions, sustaining its leadership in the global in vitro diagnostics (IVD) market landscape. This dominance is expected to persist as North America remains a hub for technological innovation, strategic investments, and a strong emphasis on healthcare excellence.

Competitive Landscape: Global In Vitro Diagnostics (IVD) Market

  • Abbott Laboratories
  • BD
  • bioMérieux SA
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • DiaSorin S.p.A.
  • Hoffmann-La Roche Ltd
  • Ortho Clinical Diagnostics.
  • QIAGEN
  • Siemens Healthineers
  • STRATEC SE (Diatron MI Zrt)
  • Sysmex Europe GmbH.
  • Thermo Fisher Scientific
  • Other Industry Participants

Global In Vitro Diagnostics (IVD) Market Summary

Report Specifications Details
Market Revenue in 2022 US$ 117.8 Bn
Market Size Forecast by 2031 US$ 217.9 Bn
Growth Rate (CAGR) 4%
Historic Data 2015 – 2021
Base Year for Estimation 2022
Forecast Period 2023 – 2031
Report Inclusions Market Size & Estimates, Market Dynamics, Competitive Scenario, Trends, Growth Factors, Market Determinants, Key Investment Segmentation, Product/Service/Solutions Benchmarking
Segments Covered By Offering, By Application, By Clinical Indication, By End Users, By Sales Channel
Regions Covered North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Countries Covered U.S., Canada, Mexico, Rest of North America,  France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe,  China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific,  Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa,  Brazil, Argentina, Rest of Latin America
Key Players Abbott Laboratories, BD, bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher., DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, Ortho Clinical Diagnostics., QIAGEN, STRATEC SE (Diatron MI Zrt), Siemens Healthineers, Sysmex Europe GmbH., Thermo Fisher Scientific, Other Market Participants
Customization Scope Customization allows for the inclusion/modification of content pertaining to geographical regions, countries, and specific market segments.
Pricing & Procurement Options Explore purchase options tailored to your specific research requirements
Contact Details Consult With Our Expert

Japan (Toll-Free):  +81 663-386-8111

South Korea (Toll-Free):  +82-808- 703-126

Saudi Arabia (Toll-Free):  +966 800-850-1643

United Kingdom: +44 753-710-5080

United States: +1 302-232-5106

E-mail:  askanexpert@thenicheresearch.com

 

Global In Vitro Diagnostics (IVD) Market ScopeBy Offering  

  • Products
    • Systems & Instruments
      • Fully Automated Systems
      • Semi-Automated Systems
      • Others
    • Assays and Reagents
    • Calibrators & Control Materials
    • Reagent Kits
    • Others
  • Software
    • Information/Data Management Software
    • Lab Automation Software
    • Others
  • Services

By Application

  • Immunoassay
  • Clinical Chemistry
  • Molecular Diagnostics
  • Hematology
  • Microbiology
  • Coagulation
  • Others

By Clinical Indication

  • Infectious Disease
    • Hepatitis
    • Coronavirus Disease (COVID-19)
    • Others
  • Oncology
  • Diabetes
  • Cardiology
  • Gynecology and Women’s Health
  • Bone Health
  • Autoimmune Diseases
  • Others

By End Users

  • Hospitals
  • Emergency Care Centers
  • Clinical Diagnostics Laboratories
  • Academic & Research Institutions
  • Home Care
  • Others

By Sales Channel

  • Direct
  • Indirect

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)

 Report Coverage & Deliverables

Table of Contents

.

1.Market Scope
1.1.Market Segmentation
1.2.Years Considered
1.2.1.Historic Years: 2015 - 2021
1.2.2.Base Year: 2022
1.2.3.Forecast Years: 2023 – 2031
2.Key Target Audiences
3.Research Methodology
3.1.Primary Research
3.1.1.Research Questionnaire
3.1.2.Global Percentage Breakdown
3.1.3.Primary Interviews: Key Opinion Leaders (KOLs)
3.2.Secondary Research
3.2.1.Paid Databases
3.2.2.Secondary Sources
3.3.Market Size Estimates
3.3.1.Top-Down Approach
3.3.2.Bottom-Up Approach
3.4.Data Triangulation Methodology
3.5.Research Assumptions
4.Recommendations and Insights from AMI’s Perspective**
5.Holistic Overview of In Vitro Diagnostics (IVD) Market
6.Market Synopsis: In Vitro Diagnostics (IVD) Market
7.In Vitro Diagnostics (IVD) Market Analysis: Qualitative Perspective
7.1.Introduction
7.1.1.Product Definition
7.1.2.Industry Development
7.2.Market Dynamics
7.2.1.Drivers
7.2.2.Restraints
7.2.3.Opportunities
7.2.4.Challenges
7.3.Trends in In Vitro Diagnostics (IVD) Market
7.4.Market Determinants Radar Chart
7.5.Macro-Economic and Micro-Economic Indicators: In Vitro Diagnostics (IVD) Market
7.6.Porter’s Five Force Analysis
7.7.Impact of Covid-19 on In Vitro Diagnostics (IVD) Market
8.Global In Vitro Diagnostics (IVD) Market Analysis and Forecasts, 2023 - 2031
8.1.Overview
8.1.1.Global In Vitro Diagnostics (IVD) Market Revenue (US$ Mn)
8.2.Global In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
8.2.1.Products (Definition, Market Estimation and Penetration, 2015 - 2022, Market Estimation (2015 - 2022), Market Forecast (2023 - 2031), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Systems and Instruments, Assays and Reagents, Calibrators and Control Materials, Reagent Kits, Others)
8.2.1.1.Systems and Instruments
8.2.1.1.1.Fully Automated Systems
8.2.1.1.2.Semi-Automated Systems
8.2.1.1.3.Others
8.2.1.2.Assays and Reagents
8.2.1.3.Calibrators and Control Materials
8.2.1.4.Reagent Kits
8.2.1.5.Others
8.2.2.Software (Definition, Market Estimation and Penetration, 2015 - 2022, Market Estimation (2015 - 2022), Market Forecast (2023 - 2031), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Information/Data Management Software, Lab Automation Software, Others)
8.2.2.1.Information/Data Management Software
8.2.2.2.Lab Automation Software
8.2.2.3.Others
8.2.3.Services
8.2.3.1.Definition
8.2.3.2.Market Estimation and Penetration, 2015 - 2022
8.2.3.3.Market Forecast, 2023 - 2031
8.2.3.4.Compound Annual Growth Rate (CAGR)
8.2.3.5.Regional Bifurcation
8.2.3.5.1.North America
8.2.3.5.1.1.Market Estimation, 2015 - 2022
8.2.3.5.1.2.Market Forecast, 2023 - 2031
8.2.3.5.2.Europe
8.2.3.5.2.1.Market Estimation, 2015 - 2022
8.2.3.5.2.2.Market Forecast, 2023 - 2031
8.2.3.5.3.Asia Pacific
8.2.3.5.3.1.Market Estimation, 2015 - 2022
8.2.3.5.3.2.Market Forecast, 2023 - 2031
8.2.3.5.4.Middle East and Africa
8.2.3.5.4.1.Market Estimation, 2015 - 2022
8.2.3.5.4.2.Market Forecast, 2023 - 2031
8.2.3.5.5.Latin America
8.2.3.5.5.1.Market Estimation, 2015 - 2022
8.2.3.5.5.2.Market Forecast, 2023 - 2031
8.3.Key Segment for Channeling Investments
8.3.1.By Offering
9.Global In Vitro Diagnostics (IVD) Market Analysis and Forecasts, 2023 - 2031
9.1.Overview
9.2.Global In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
9.2.1.Immunoassay
9.2.1.1.Definition
9.2.1.2.Market Estimation and Penetration, 2015 - 2022
9.2.1.3.Market Forecast, 2023 - 2031
9.2.1.4.Compound Annual Growth Rate (CAGR)
9.2.1.5.Regional Bifurcation
9.2.1.5.1.North America
9.2.1.5.1.1.Market Estimation, 2015 - 2022
9.2.1.5.1.2.Market Forecast, 2023 - 2031
9.2.1.5.2.Europe
9.2.1.5.2.1.Market Estimation, 2015 - 2022
9.2.1.5.2.2.Market Forecast, 2023 - 2031
9.2.1.5.3.Asia Pacific
9.2.1.5.3.1.Market Estimation, 2015 - 2022
9.2.1.5.3.2.Market Forecast, 2023 - 2031
9.2.1.5.4.Middle East and Africa
9.2.1.5.4.1.Market Estimation, 2015 - 2022
9.2.1.5.4.2.Market Forecast, 2023 - 2031
9.2.1.5.5.Latin America
9.2.1.5.5.1.Market Estimation, 2015 - 2022
9.2.1.5.5.2.Market Forecast, 2023 - 2031
9.2.2.Clinical Chemistry
9.2.2.1.Definition
9.2.2.2.Market Estimation and Penetration, 2015 - 2022
9.2.2.3.Market Forecast, 2023 - 2031
9.2.2.4.Compound Annual Growth Rate (CAGR)
9.2.2.5.Regional Bifurcation
9.2.2.5.1.North America
9.2.2.5.1.1.Market Estimation, 2015 - 2022
9.2.2.5.1.2.Market Forecast, 2023 - 2031
9.2.2.5.2.Europe
9.2.2.5.2.1.Market Estimation, 2015 - 2022
9.2.2.5.2.2.Market Forecast, 2023 - 2031
9.2.2.5.3.Asia Pacific
9.2.2.5.3.1.Market Estimation, 2015 - 2022
9.2.2.5.3.2.Market Forecast, 2023 - 2031
9.2.2.5.4.Middle East and Africa
9.2.2.5.4.1.Market Estimation, 2015 - 2022
9.2.2.5.4.2.Market Forecast, 2023 - 2031
9.2.2.5.5.Latin America
9.2.2.5.5.1.Market Estimation, 2015 - 2022
9.2.2.5.5.2.Market Forecast, 2023 - 2031
9.2.3.Molecular Diagnostics
9.2.3.1.Definition
9.2.3.2.Market Estimation and Penetration, 2015 - 2022
9.2.3.3.Market Forecast, 2023 - 2031
9.2.3.4.Compound Annual Growth Rate (CAGR)
9.2.3.5.Regional Bifurcation
9.2.3.5.1.North America
9.2.3.5.1.1.Market Estimation, 2015 - 2022
9.2.3.5.1.2.Market Forecast, 2023 - 2031
9.2.3.5.2.Europe
9.2.3.5.2.1.Market Estimation, 2015 - 2022
9.2.3.5.2.2.Market Forecast, 2023 - 2031
9.2.3.5.3.Asia Pacific
9.2.3.5.3.1.Market Estimation, 2015 - 2022
9.2.3.5.3.2.Market Forecast, 2023 - 2031
9.2.3.5.4.Middle East and Africa
9.2.3.5.4.1.Market Estimation, 2015 - 2022
9.2.3.5.4.2.Market Forecast, 2023 - 2031
9.2.3.5.5.Latin America
9.2.3.5.5.1.Market Estimation, 2015 - 2022
9.2.3.5.5.2.Market Forecast, 2023 - 2031
9.2.4.Hematology
9.2.4.1.Definition
9.2.4.2.Market Estimation and Penetration, 2015 - 2022
9.2.4.3.Market Forecast, 2023 - 2031
9.2.4.4.Compound Annual Growth Rate (CAGR)
9.2.4.5.Regional Bifurcation
9.2.4.5.1.North America
9.2.4.5.1.1.Market Estimation, 2015 - 2022
9.2.4.5.1.2.Market Forecast, 2023 - 2031
9.2.4.5.2.Europe
9.2.4.5.2.1.Market Estimation, 2015 - 2022
9.2.4.5.2.2.Market Forecast, 2023 - 2031
9.2.4.5.3.Asia Pacific
9.2.4.5.3.1.Market Estimation, 2015 - 2022
9.2.4.5.3.2.Market Forecast, 2023 - 2031
9.2.4.5.4.Middle East and Africa
9.2.4.5.4.1.Market Estimation, 2015 - 2022
9.2.4.5.4.2.Market Forecast, 2023 - 2031
9.2.4.5.5.Latin America
9.2.4.5.5.1.Market Estimation, 2015 - 2022
9.2.4.5.5.2.Market Forecast, 2023 - 2031
9.2.5.Microbiology
9.2.5.1.Definition
9.2.5.2.Market Estimation and Penetration, 2015 - 2022
9.2.5.3.Market Forecast, 2023 - 2031
9.2.5.4.Compound Annual Growth Rate (CAGR)
9.2.5.5.Regional Bifurcation
9.2.5.5.1.North America
9.2.5.5.1.1.Market Estimation, 2015 - 2022
9.2.5.5.1.2.Market Forecast, 2023 - 2031
9.2.5.5.2.Europe
9.2.5.5.2.1.Market Estimation, 2015 - 2022
9.2.5.5.2.2.Market Forecast, 2023 - 2031
9.2.5.5.3.Asia Pacific
9.2.5.5.3.1.Market Estimation, 2015 - 2022
9.2.5.5.3.2.Market Forecast, 2023 - 2031
9.2.5.5.4.Middle East and Africa
9.2.5.5.4.1.Market Estimation, 2015 - 2022
9.2.5.5.4.2.Market Forecast, 2023 - 2031
9.2.5.5.5.Latin America
9.2.5.5.5.1.Market Estimation, 2015 - 2022
9.2.5.5.5.2.Market Forecast, 2023 - 2031
9.2.6.Coagulation
9.2.6.1.Definition
9.2.6.2.Market Estimation and Penetration, 2015 - 2022
9.2.6.3.Market Forecast, 2023 - 2031
9.2.6.4.Compound Annual Growth Rate (CAGR)
9.2.6.5.Regional Bifurcation
9.2.6.5.1.North America
9.2.6.5.1.1.Market Estimation, 2015 - 2022
9.2.6.5.1.2.Market Forecast, 2023 - 2031
9.2.6.5.2.Europe
9.2.6.5.2.1.Market Estimation, 2015 - 2022
9.2.6.5.2.2.Market Forecast, 2023 - 2031
9.2.6.5.3.Asia Pacific
9.2.6.5.3.1.Market Estimation, 2015 - 2022
9.2.6.5.3.2.Market Forecast, 2023 - 2031
9.2.6.5.4.Middle East and Africa
9.2.6.5.4.1.Market Estimation, 2015 - 2022
9.2.6.5.4.2.Market Forecast, 2023 - 2031
9.2.6.5.5.Latin America
9.2.6.5.5.1.Market Estimation, 2015 - 2022
9.2.6.5.5.2.Market Forecast, 2023 - 2031
9.2.7.Others
9.2.7.1.Definition
9.2.7.2.Market Estimation and Penetration, 2015 - 2022
9.2.7.3.Market Forecast, 2023 - 2031
9.2.7.4.Compound Annual Growth Rate (CAGR)
9.2.7.5.Regional Bifurcation
9.2.7.5.1.North America
9.2.7.5.1.1.Market Estimation, 2015 - 2022
9.2.7.5.1.2.Market Forecast, 2023 - 2031
9.2.7.5.2.Europe
9.2.7.5.2.1.Market Estimation, 2015 - 2022
9.2.7.5.2.2.Market Forecast, 2023 - 2031
9.2.7.5.3.Asia Pacific
9.2.7.5.3.1.Market Estimation, 2015 - 2022
9.2.7.5.3.2.Market Forecast, 2023 - 2031
9.2.7.5.4.Middle East and Africa
9.2.7.5.4.1.Market Estimation, 2015 - 2022
9.2.7.5.4.2.Market Forecast, 2023 - 2031
9.2.7.5.5.Latin America
9.2.7.5.5.1.Market Estimation, 2015 - 2022
9.2.7.5.5.2.Market Forecast, 2023 - 2031
9.3.Key Segment for Channeling Investments
9.3.1.By Application
10.Global In Vitro Diagnostics (IVD) Market Analysis and Forecasts, 2023 - 2031
10.1.Overview
10.2.Global In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
10.2.1.Infectious Disease (Definition, Market Estimation and Penetration, 2015 - 2022, Market Estimation (2015 - 2022), Market Forecast (2023 - 2031), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Hepatitis, Coronavirus Disease (COVID-19), Others)
10.2.1.1.Hepatitis
10.2.1.2.Coronavirus Disease (COVID-19)
10.2.1.3.Others
10.2.2.Oncology
10.2.2.1.Definition
10.2.2.2.Market Estimation and Penetration, 2015 - 2022
10.2.2.3.Market Forecast, 2023 - 2031
10.2.2.4.Compound Annual Growth Rate (CAGR)
10.2.2.5.Regional Bifurcation
10.2.2.5.1.North America
10.2.2.5.1.1.Market Estimation, 2015 - 2022
10.2.2.5.1.2.Market Forecast, 2023 - 2031
10.2.2.5.2.Europe
10.2.2.5.2.1.Market Estimation, 2015 - 2022
10.2.2.5.2.2.Market Forecast, 2023 - 2031
10.2.2.5.3.Asia Pacific
10.2.2.5.3.1.Market Estimation, 2015 - 2022
10.2.2.5.3.2.Market Forecast, 2023 - 2031
10.2.2.5.4.Middle East and Africa
10.2.2.5.4.1.Market Estimation, 2015 - 2022
10.2.2.5.4.2.Market Forecast, 2023 - 2031
10.2.2.5.5.Latin America
10.2.2.5.5.1.Market Estimation, 2015 - 2022
10.2.2.5.5.2.Market Forecast, 2023 - 2031
10.2.3.Diabetes
10.2.3.1.Definition
10.2.3.2.Market Estimation and Penetration, 2015 - 2022
10.2.3.3.Market Forecast, 2023 - 2031
10.2.3.4.Compound Annual Growth Rate (CAGR)
10.2.3.5.Regional Bifurcation
10.2.3.5.1.North America
10.2.3.5.1.1.Market Estimation, 2015 - 2022
10.2.3.5.1.2.Market Forecast, 2023 - 2031
10.2.3.5.2.Europe
10.2.3.5.2.1.Market Estimation, 2015 - 2022
10.2.3.5.2.2.Market Forecast, 2023 - 2031
10.2.3.5.3.Asia Pacific
10.2.3.5.3.1.Market Estimation, 2015 - 2022
10.2.3.5.3.2.Market Forecast, 2023 - 2031
10.2.3.5.4.Middle East and Africa
10.2.3.5.4.1.Market Estimation, 2015 - 2022
10.2.3.5.4.2.Market Forecast, 2023 - 2031
10.2.3.5.5.Latin America
10.2.3.5.5.1.Market Estimation, 2015 - 2022
10.2.3.5.5.2.Market Forecast, 2023 - 2031
10.2.4.Cardiology
10.2.4.1.Definition
10.2.4.2.Market Estimation and Penetration, 2015 - 2022
10.2.4.3.Market Forecast, 2023 - 2031
10.2.4.4.Compound Annual Growth Rate (CAGR)
10.2.4.5.Regional Bifurcation
10.2.4.5.1.North America
10.2.4.5.1.1.Market Estimation, 2015 - 2022
10.2.4.5.1.2.Market Forecast, 2023 - 2031
10.2.4.5.2.Europe
10.2.4.5.2.1.Market Estimation, 2015 - 2022
10.2.4.5.2.2.Market Forecast, 2023 - 2031
10.2.4.5.3.Asia Pacific
10.2.4.5.3.1.Market Estimation, 2015 - 2022
10.2.4.5.3.2.Market Forecast, 2023 - 2031
10.2.4.5.4.Middle East and Africa
10.2.4.5.4.1.Market Estimation, 2015 - 2022
10.2.4.5.4.2.Market Forecast, 2023 - 2031
10.2.4.5.5.Latin America
10.2.4.5.5.1.Market Estimation, 2015 - 2022
10.2.4.5.5.2.Market Forecast, 2023 - 2031
10.2.5.Gynecology and Women’s Health
10.2.5.1.Definition
10.2.5.2.Market Estimation and Penetration, 2015 - 2022
10.2.5.3.Market Forecast, 2023 - 2031
10.2.5.4.Compound Annual Growth Rate (CAGR)
10.2.5.5.Regional Bifurcation
10.2.5.5.1.North America
10.2.5.5.1.1.Market Estimation, 2015 - 2022
10.2.5.5.1.2.Market Forecast, 2023 - 2031
10.2.5.5.2.Europe
10.2.5.5.2.1.Market Estimation, 2015 - 2022
10.2.5.5.2.2.Market Forecast, 2023 - 2031
10.2.5.5.3.Asia Pacific
10.2.5.5.3.1.Market Estimation, 2015 - 2022
10.2.5.5.3.2.Market Forecast, 2023 - 2031
10.2.5.5.4.Middle East and Africa
10.2.5.5.4.1.Market Estimation, 2015 - 2022
10.2.5.5.4.2.Market Forecast, 2023 - 2031
10.2.5.5.5.Latin America
10.2.5.5.5.1.Market Estimation, 2015 - 2022
10.2.5.5.5.2.Market Forecast, 2023 - 2031
10.2.6.Bone Health
10.2.6.1.Definition
10.2.6.2.Market Estimation and Penetration, 2015 - 2022
10.2.6.3.Market Forecast, 2023 - 2031
10.2.6.4.Compound Annual Growth Rate (CAGR)
10.2.6.5.Regional Bifurcation
10.2.6.5.1.North America
10.2.6.5.1.1.Market Estimation, 2015 - 2022
10.2.6.5.1.2.Market Forecast, 2023 - 2031
10.2.6.5.2.Europe
10.2.6.5.2.1.Market Estimation, 2015 - 2022
10.2.6.5.2.2.Market Forecast, 2023 - 2031
10.2.6.5.3.Asia Pacific
10.2.6.5.3.1.Market Estimation, 2015 - 2022
10.2.6.5.3.2.Market Forecast, 2023 - 2031
10.2.6.5.4.Middle East and Africa
10.2.6.5.4.1.Market Estimation, 2015 - 2022
10.2.6.5.4.2.Market Forecast, 2023 - 2031
10.2.6.5.5.Latin America
10.2.6.5.5.1.Market Estimation, 2015 - 2022
10.2.6.5.5.2.Market Forecast, 2023 - 2031
10.2.7.Autoimmune Diseases
10.2.7.1.Definition
10.2.7.2.Market Estimation and Penetration, 2015 - 2022
10.2.7.3.Market Forecast, 2023 - 2031
10.2.7.4.Compound Annual Growth Rate (CAGR)
10.2.7.5.Regional Bifurcation
10.2.7.5.1.North America
10.2.7.5.1.1.Market Estimation, 2015 - 2022
10.2.7.5.1.2.Market Forecast, 2023 - 2031
10.2.7.5.2.Europe
10.2.7.5.2.1.Market Estimation, 2015 - 2022
10.2.7.5.2.2.Market Forecast, 2023 - 2031
10.2.7.5.3.Asia Pacific
10.2.7.5.3.1.Market Estimation, 2015 - 2022
10.2.7.5.3.2.Market Forecast, 2023 - 2031
10.2.7.5.4.Middle East and Africa
10.2.7.5.4.1.Market Estimation, 2015 - 2022
10.2.7.5.4.2.Market Forecast, 2023 - 2031
10.2.7.5.5.Latin America
10.2.7.5.5.1.Market Estimation, 2015 - 2022
10.2.7.5.5.2.Market Forecast, 2023 - 2031
10.2.8.Others
10.2.8.1.Definition
10.2.8.2.Market Estimation and Penetration, 2015 - 2022
10.2.8.3.Market Forecast, 2023 - 2031
10.2.8.4.Compound Annual Growth Rate (CAGR)
10.2.8.5.Regional Bifurcation
10.2.8.5.1.North America
10.2.8.5.1.1.Market Estimation, 2015 - 2022
10.2.8.5.1.2.Market Forecast, 2023 - 2031
10.2.8.5.2.Europe
10.2.8.5.2.1.Market Estimation, 2015 - 2022
10.2.8.5.2.2.Market Forecast, 2023 - 2031
10.2.8.5.3.Asia Pacific
10.2.8.5.3.1.Market Estimation, 2015 - 2022
10.2.8.5.3.2.Market Forecast, 2023 - 2031
10.2.8.5.4.Middle East and Africa
10.2.8.5.4.1.Market Estimation, 2015 - 2022
10.2.8.5.4.2.Market Forecast, 2023 - 2031
10.2.8.5.5.Latin America
10.2.8.5.5.1.Market Estimation, 2015 - 2022
10.2.8.5.5.2.Market Forecast, 2023 - 2031
10.3.Key Segment for Channeling Investments
10.3.1.By Clinical Indication
11.Global In Vitro Diagnostics (IVD) Market Analysis and Forecasts, 2023 - 2031
11.1.Overview
11.2.Global In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
11.2.1.Hospitals
11.2.1.1.Definition
11.2.1.2.Market Estimation and Penetration, 2015 - 2022
11.2.1.3.Market Forecast, 2023 - 2031
11.2.1.4.Compound Annual Growth Rate (CAGR)
11.2.1.5.Regional Bifurcation
11.2.1.5.1.North America
11.2.1.5.1.1.Market Estimation, 2015 - 2022
11.2.1.5.1.2.Market Forecast, 2023 - 2031
11.2.1.5.2.Europe
11.2.1.5.2.1.Market Estimation, 2015 - 2022
11.2.1.5.2.2.Market Forecast, 2023 - 2031
11.2.1.5.3.Asia Pacific
11.2.1.5.3.1.Market Estimation, 2015 - 2022
11.2.1.5.3.2.Market Forecast, 2023 - 2031
11.2.1.5.4.Middle East and Africa
11.2.1.5.4.1.Market Estimation, 2015 - 2022
11.2.1.5.4.2.Market Forecast, 2023 - 2031
11.2.1.5.5.Latin America
11.2.1.5.5.1.Market Estimation, 2015 - 2022
11.2.1.5.5.2.Market Forecast, 2023 - 2031
11.2.2.Emergency Care Centers
11.2.2.1.Definition
11.2.2.2.Market Estimation and Penetration, 2015 - 2022
11.2.2.3.Market Forecast, 2023 - 2031
11.2.2.4.Compound Annual Growth Rate (CAGR)
11.2.2.5.Regional Bifurcation
11.2.2.5.1.North America
11.2.2.5.1.1.Market Estimation, 2015 - 2022
11.2.2.5.1.2.Market Forecast, 2023 - 2031
11.2.2.5.2.Europe
11.2.2.5.2.1.Market Estimation, 2015 - 2022
11.2.2.5.2.2.Market Forecast, 2023 - 2031
11.2.2.5.3.Asia Pacific
11.2.2.5.3.1.Market Estimation, 2015 - 2022
11.2.2.5.3.2.Market Forecast, 2023 - 2031
11.2.2.5.4.Middle East and Africa
11.2.2.5.4.1.Market Estimation, 2015 - 2022
11.2.2.5.4.2.Market Forecast, 2023 - 2031
11.2.2.5.5.Latin America
11.2.2.5.5.1.Market Estimation, 2015 - 2022
11.2.2.5.5.2.Market Forecast, 2023 - 2031
11.2.3.Clinical Diagnostics Laboratories
11.2.3.1.Definition
11.2.3.2.Market Estimation and Penetration, 2015 - 2022
11.2.3.3.Market Forecast, 2023 - 2031
11.2.3.4.Compound Annual Growth Rate (CAGR)
11.2.3.5.Regional Bifurcation
11.2.3.5.1.North America
11.2.3.5.1.1.Market Estimation, 2015 - 2022
11.2.3.5.1.2.Market Forecast, 2023 - 2031
11.2.3.5.2.Europe
11.2.3.5.2.1.Market Estimation, 2015 - 2022
11.2.3.5.2.2.Market Forecast, 2023 - 2031
11.2.3.5.3.Asia Pacific
11.2.3.5.3.1.Market Estimation, 2015 - 2022
11.2.3.5.3.2.Market Forecast, 2023 - 2031
11.2.3.5.4.Middle East and Africa
11.2.3.5.4.1.Market Estimation, 2015 - 2022
11.2.3.5.4.2.Market Forecast, 2023 - 2031
11.2.3.5.5.Latin America
11.2.3.5.5.1.Market Estimation, 2015 - 2022
11.2.3.5.5.2.Market Forecast, 2023 - 2031
11.2.4.Academic and Research Institutions
11.2.4.1.Definition
11.2.4.2.Market Estimation and Penetration, 2015 - 2022
11.2.4.3.Market Forecast, 2023 - 2031
11.2.4.4.Compound Annual Growth Rate (CAGR)
11.2.4.5.Regional Bifurcation
11.2.4.5.1.North America
11.2.4.5.1.1.Market Estimation, 2015 - 2022
11.2.4.5.1.2.Market Forecast, 2023 - 2031
11.2.4.5.2.Europe
11.2.4.5.2.1.Market Estimation, 2015 - 2022
11.2.4.5.2.2.Market Forecast, 2023 - 2031
11.2.4.5.3.Asia Pacific
11.2.4.5.3.1.Market Estimation, 2015 - 2022
11.2.4.5.3.2.Market Forecast, 2023 - 2031
11.2.4.5.4.Middle East and Africa
11.2.4.5.4.1.Market Estimation, 2015 - 2022
11.2.4.5.4.2.Market Forecast, 2023 - 2031
11.2.4.5.5.Latin America
11.2.4.5.5.1.Market Estimation, 2015 - 2022
11.2.4.5.5.2.Market Forecast, 2023 - 2031
11.2.5.Home Care
11.2.5.1.Definition
11.2.5.2.Market Estimation and Penetration, 2015 - 2022
11.2.5.3.Market Forecast, 2023 - 2031
11.2.5.4.Compound Annual Growth Rate (CAGR)
11.2.5.5.Regional Bifurcation
11.2.5.5.1.North America
11.2.5.5.1.1.Market Estimation, 2015 - 2022
11.2.5.5.1.2.Market Forecast, 2023 - 2031
11.2.5.5.2.Europe
11.2.5.5.2.1.Market Estimation, 2015 - 2022
11.2.5.5.2.2.Market Forecast, 2023 - 2031
11.2.5.5.3.Asia Pacific
11.2.5.5.3.1.Market Estimation, 2015 - 2022
11.2.5.5.3.2.Market Forecast, 2023 - 2031
11.2.5.5.4.Middle East and Africa
11.2.5.5.4.1.Market Estimation, 2015 - 2022
11.2.5.5.4.2.Market Forecast, 2023 - 2031
11.2.5.5.5.Latin America
11.2.5.5.5.1.Market Estimation, 2015 - 2022
11.2.5.5.5.2.Market Forecast, 2023 - 2031
11.2.6.Others
11.2.6.1.Definition
11.2.6.2.Market Estimation and Penetration, 2015 - 2022
11.2.6.3.Market Forecast, 2023 - 2031
11.2.6.4.Compound Annual Growth Rate (CAGR)
11.2.6.5.Regional Bifurcation
11.2.6.5.1.North America
11.2.6.5.1.1.Market Estimation, 2015 - 2022
11.2.6.5.1.2.Market Forecast, 2023 - 2031
11.2.6.5.2.Europe
11.2.6.5.2.1.Market Estimation, 2015 - 2022
11.2.6.5.2.2.Market Forecast, 2023 - 2031
11.2.6.5.3.Asia Pacific
11.2.6.5.3.1.Market Estimation, 2015 - 2022
11.2.6.5.3.2.Market Forecast, 2023 - 2031
11.2.6.5.4.Middle East and Africa
11.2.6.5.4.1.Market Estimation, 2015 - 2022
11.2.6.5.4.2.Market Forecast, 2023 - 2031
11.2.6.5.5.Latin America
11.2.6.5.5.1.Market Estimation, 2015 - 2022
11.2.6.5.5.2.Market Forecast, 2023 - 2031
11.3.Key Segment for Channeling Investments
11.3.1.By End Users
12.Global In Vitro Diagnostics (IVD) Market Analysis and Forecasts, 2023 - 2031
12.1.Overview
12.2.Global In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
12.2.1.Direct
12.2.1.1.Definition
12.2.1.2.Market Estimation and Penetration, 2015 - 2022
12.2.1.3.Market Forecast, 2023 - 2031
12.2.1.4.Compound Annual Growth Rate (CAGR)
12.2.1.5.Regional Bifurcation
12.2.1.5.1.North America
12.2.1.5.1.1.Market Estimation, 2015 - 2022
12.2.1.5.1.2.Market Forecast, 2023 - 2031
12.2.1.5.2.Europe
12.2.1.5.2.1.Market Estimation, 2015 - 2022
12.2.1.5.2.2.Market Forecast, 2023 - 2031
12.2.1.5.3.Asia Pacific
12.2.1.5.3.1.Market Estimation, 2015 - 2022
12.2.1.5.3.2.Market Forecast, 2023 - 2031
12.2.1.5.4.Middle East and Africa
12.2.1.5.4.1.Market Estimation, 2015 - 2022
12.2.1.5.4.2.Market Forecast, 2023 - 2031
12.2.1.5.5.Latin America
12.2.1.5.5.1.Market Estimation, 2015 - 2022
12.2.1.5.5.2.Market Forecast, 2023 - 2031
12.2.2.Indirect
12.2.2.1.Definition
12.2.2.2.Market Estimation and Penetration, 2015 - 2022
12.2.2.3.Market Forecast, 2023 - 2031
12.2.2.4.Compound Annual Growth Rate (CAGR)
12.2.2.5.Regional Bifurcation
12.2.2.5.1.North America
12.2.2.5.1.1.Market Estimation, 2015 - 2022
12.2.2.5.1.2.Market Forecast, 2023 - 2031
12.2.2.5.2.Europe
12.2.2.5.2.1.Market Estimation, 2015 - 2022
12.2.2.5.2.2.Market Forecast, 2023 - 2031
12.2.2.5.3.Asia Pacific
12.2.2.5.3.1.Market Estimation, 2015 - 2022
12.2.2.5.3.2.Market Forecast, 2023 - 2031
12.2.2.5.4.Middle East and Africa
12.2.2.5.4.1.Market Estimation, 2015 - 2022
12.2.2.5.4.2.Market Forecast, 2023 - 2031
12.2.2.5.5.Latin America
12.2.2.5.5.1.Market Estimation, 2015 - 2022
12.2.2.5.5.2.Market Forecast, 2023 - 2031
12.3.Key Segment for Channeling Investments
12.3.1.By Sales Channel
13.North America In Vitro Diagnostics (IVD) Market Analysis and Forecasts, 2023 - 2031
13.1.Overview
13.1.1.North America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn)
13.2.North America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
13.2.1.Products
13.2.1.1.Systems and Instruments
13.2.1.1.1.Fully Automated Systems
13.2.1.1.2.Semi-Automated Systems
13.2.1.1.3.Others
13.2.1.2.Assays and Reagents
13.2.1.3.Calibrators and Control Materials
13.2.1.4.Reagent Kits
13.2.1.5.Others
13.2.2.Software
13.2.2.1.Information/Data Management Software
13.2.2.2.Lab Automation Software
13.2.2.3.Others
13.2.3.Services
13.3.North America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
13.3.1.Immunoassay
13.3.2.Clinical Chemistry
13.3.3.Molecular Diagnostics
13.3.4.Hematology
13.3.5.Microbiology
13.3.6.Coagulation
13.3.7.Others
13.4.North America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
13.4.1.Infectious Disease
13.4.1.1.Hepatitis
13.4.1.2.Coronavirus Disease (COVID-19)
13.4.1.3.Others
13.4.2.Oncology
13.4.3.Diabetes
13.4.4.Cardiology
13.4.5.Gynecology and Women’s Health
13.4.6.Bone Health
13.4.7.Autoimmune Diseases
13.4.8.Others
13.5.North America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.1.Hospitals
13.5.2.Emergency Care Centers
13.5.3.Clinical Diagnostics Laboratories
13.5.4.Academic and Research Institutions
13.5.5.Home Care
13.5.6.Others
13.6.North America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
13.6.1.Direct
13.6.2.Indirect
13.7.North America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Country
13.7.1.U.S
13.7.1.1.U.S In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
13.7.1.1.1.Products
13.7.1.1.1.1.Systems and Instruments
13.7.1.1.1.1.1.Fully Automated Systems
13.7.1.1.1.1.2.Semi-Automated Systems
13.7.1.1.1.1.3.Others
13.7.1.1.1.2.Assays and Reagents
13.7.1.1.1.3.Calibrators and Control Materials
13.7.1.1.1.4.Reagent Kits
13.7.1.1.1.5.Others
13.7.1.1.2.Software
13.7.1.1.2.1.Information/Data Management Software
13.7.1.1.2.2.Lab Automation Software
13.7.1.1.2.3.Others
13.7.1.1.3.Services
13.7.1.2.U.S In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
13.7.1.2.1.Immunoassay
13.7.1.2.2.Clinical Chemistry
13.7.1.2.3.Molecular Diagnostics
13.7.1.2.4.Hematology
13.7.1.2.5.Microbiology
13.7.1.2.6.Coagulation
13.7.1.2.7.Others
13.7.1.3.U.S In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
13.7.1.3.1.Infectious Disease
13.7.1.3.1.1.Hepatitis
13.7.1.3.1.2.Coronavirus Disease (COVID-19)
13.7.1.3.1.3.Others
13.7.1.3.2.Oncology
13.7.1.3.3.Diabetes
13.7.1.3.4.Cardiology
13.7.1.3.5.Gynecology and Women’s Health
13.7.1.3.6.Bone Health
13.7.1.3.7.Autoimmune Diseases
13.7.1.3.8.Others
13.7.1.4.U.S In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
13.7.1.4.1.Hospitals
13.7.1.4.2.Emergency Care Centers
13.7.1.4.3.Clinical Diagnostics Laboratories
13.7.1.4.4.Academic and Research Institutions
13.7.1.4.5.Home Care
13.7.1.4.6.Others
13.7.1.5.U.S In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
13.7.1.5.1.Direct
13.7.1.5.2.Indirect
13.7.2.Canada
13.7.2.1.Canada In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
13.7.2.1.1.Products
13.7.2.1.1.1.Systems and Instruments
13.7.2.1.1.1.1.Fully Automated Systems
13.7.2.1.1.1.2.Semi-Automated Systems
13.7.2.1.1.1.3.Others
13.7.2.1.1.2.Assays and Reagents
13.7.2.1.1.3.Calibrators and Control Materials
13.7.2.1.1.4.Reagent Kits
13.7.2.1.1.5.Others
13.7.2.1.2.Software
13.7.2.1.2.1.Information/Data Management Software
13.7.2.1.2.2.Lab Automation Software
13.7.2.1.2.3.Others
13.7.2.1.3.Services
13.7.2.2.Canada In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
13.7.2.2.1.Immunoassay
13.7.2.2.2.Clinical Chemistry
13.7.2.2.3.Molecular Diagnostics
13.7.2.2.4.Hematology
13.7.2.2.5.Microbiology
13.7.2.2.6.Coagulation
13.7.2.2.7.Others
13.7.2.3.Canada In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
13.7.2.3.1.Infectious Disease
13.7.2.3.1.1.Hepatitis
13.7.2.3.1.2.Coronavirus Disease (COVID-19)
13.7.2.3.1.3.Others
13.7.2.3.2.Oncology
13.7.2.3.3.Diabetes
13.7.2.3.4.Cardiology
13.7.2.3.5.Gynecology and Women’s Health
13.7.2.3.6.Bone Health
13.7.2.3.7.Autoimmune Diseases
13.7.2.3.8.Others
13.7.2.4.Canada In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
13.7.2.4.1.Hospitals
13.7.2.4.2.Emergency Care Centers
13.7.2.4.3.Clinical Diagnostics Laboratories
13.7.2.4.4.Academic and Research Institutions
13.7.2.4.5.Home Care
13.7.2.4.6.Others
13.7.2.5.Canada In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
13.7.2.5.1.Direct
13.7.2.5.2.Indirect
13.7.3.Mexico
13.7.3.1.Mexico In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
13.7.3.1.1.Products
13.7.3.1.1.1.Systems and Instruments
13.7.3.1.1.1.1.Fully Automated Systems
13.7.3.1.1.1.2.Semi-Automated Systems
13.7.3.1.1.1.3.Others
13.7.3.1.1.2.Assays and Reagents
13.7.3.1.1.3.Calibrators and Control Materials
13.7.3.1.1.4.Reagent Kits
13.7.3.1.1.5.Others
13.7.3.1.2.Software
13.7.3.1.2.1.Information/Data Management Software
13.7.3.1.2.2.Lab Automation Software
13.7.3.1.2.3.Others
13.7.3.1.3.Services
13.7.3.2.Mexico In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
13.7.3.2.1.Immunoassay
13.7.3.2.2.Clinical Chemistry
13.7.3.2.3.Molecular Diagnostics
13.7.3.2.4.Hematology
13.7.3.2.5.Microbiology
13.7.3.2.6.Coagulation
13.7.3.2.7.Others
13.7.3.3.Mexico In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
13.7.3.3.1.Infectious Disease
13.7.3.3.1.1.Hepatitis
13.7.3.3.1.2.Coronavirus Disease (COVID-19)
13.7.3.3.1.3.Others
13.7.3.3.2.Oncology
13.7.3.3.3.Diabetes
13.7.3.3.4.Cardiology
13.7.3.3.5.Gynecology and Women’s Health
13.7.3.3.6.Bone Health
13.7.3.3.7.Autoimmune Diseases
13.7.3.3.8.Others
13.7.3.4.Mexico In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
13.7.3.4.1.Hospitals
13.7.3.4.2.Emergency Care Centers
13.7.3.4.3.Clinical Diagnostics Laboratories
13.7.3.4.4.Academic and Research Institutions
13.7.3.4.5.Home Care
13.7.3.4.6.Others
13.7.3.5.Mexico In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
13.7.3.5.1.Direct
13.7.3.5.2.Indirect
13.7.4.Rest of North America
13.7.4.1.Rest of North America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
13.7.4.1.1.Products
13.7.4.1.1.1.Systems and Instruments
13.7.4.1.1.1.1.Fully Automated Systems
13.7.4.1.1.1.2.Semi-Automated Systems
13.7.4.1.1.1.3.Others
13.7.4.1.1.2.Assays and Reagents
13.7.4.1.1.3.Calibrators and Control Materials
13.7.4.1.1.4.Reagent Kits
13.7.4.1.1.5.Others
13.7.4.1.2.Software
13.7.4.1.2.1.Information/Data Management Software
13.7.4.1.2.2.Lab Automation Software
13.7.4.1.2.3.Others
13.7.4.1.3.Services
13.7.4.2.Rest of North America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
13.7.4.2.1.Immunoassay
13.7.4.2.2.Clinical Chemistry
13.7.4.2.3.Molecular Diagnostics
13.7.4.2.4.Hematology
13.7.4.2.5.Microbiology
13.7.4.2.6.Coagulation
13.7.4.2.7.Others
13.7.4.3.Rest of North America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
13.7.4.3.1.Infectious Disease
13.7.4.3.1.1.Hepatitis
13.7.4.3.1.2.Coronavirus Disease (COVID-19)
13.7.4.3.1.3.Others
13.7.4.3.2.Oncology
13.7.4.3.3.Diabetes
13.7.4.3.4.Cardiology
13.7.4.3.5.Gynecology and Women’s Health
13.7.4.3.6.Bone Health
13.7.4.3.7.Autoimmune Diseases
13.7.4.3.8.Others
13.7.4.4.Rest of North America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
13.7.4.4.1.Hospitals
13.7.4.4.2.Emergency Care Centers
13.7.4.4.3.Clinical Diagnostics Laboratories
13.7.4.4.4.Academic and Research Institutions
13.7.4.4.5.Home Care
13.7.4.4.6.Others
13.7.4.5.Rest of North America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
13.7.4.5.1.Direct
13.7.4.5.2.Indirect
13.8.Key Segment for Channeling Investments
13.8.1.By Country
13.8.2.By Offering
13.8.3.By Application
13.8.4.By Clinical Indication
13.8.5.By End Users
13.8.6.By Sales Channel
14.Europe In Vitro Diagnostics (IVD) Market Analysis and Forecasts, 2023 - 2031
14.1.Overview
14.1.1.Europe In Vitro Diagnostics (IVD) Market Revenue (US$ Mn)
14.2.Europe In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
14.2.1.Products
14.2.1.1.Systems and Instruments
14.2.1.1.1.Fully Automated Systems
14.2.1.1.2.Semi-Automated Systems
14.2.1.1.3.Others
14.2.1.2.Assays and Reagents
14.2.1.3.Calibrators and Control Materials
14.2.1.4.Reagent Kits
14.2.1.5.Others
14.2.2.Software
14.2.2.1.Information/Data Management Software
14.2.2.2.Lab Automation Software
14.2.2.3.Others
14.2.3.Services
14.3.Europe In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
14.3.1.Immunoassay
14.3.2.Clinical Chemistry
14.3.3.Molecular Diagnostics
14.3.4.Hematology
14.3.5.Microbiology
14.3.6.Coagulation
14.3.7.Others
14.4.Europe In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
14.4.1.Infectious Disease
14.4.1.1.Hepatitis
14.4.1.2.Coronavirus Disease (COVID-19)
14.4.1.3.Others
14.4.2.Oncology
14.4.3.Diabetes
14.4.4.Cardiology
14.4.5.Gynecology and Women’s Health
14.4.6.Bone Health
14.4.7.Autoimmune Diseases
14.4.8.Others
14.5.Europe In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
14.5.1.Hospitals
14.5.2.Emergency Care Centers
14.5.3.Clinical Diagnostics Laboratories
14.5.4.Academic and Research Institutions
14.5.5.Home Care
14.5.6.Others
14.6.Europe In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
14.6.1.Direct
14.6.2.Indirect
14.7.Europe In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Country
14.7.1.France
14.7.1.1.France In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
14.7.1.1.1.Products
14.7.1.1.1.1.Systems and Instruments
14.7.1.1.1.1.1.Fully Automated Systems
14.7.1.1.1.1.2.Semi-Automated Systems
14.7.1.1.1.1.3.Others
14.7.1.1.1.2.Assays and Reagents
14.7.1.1.1.3.Calibrators and Control Materials
14.7.1.1.1.4.Reagent Kits
14.7.1.1.1.5.Others
14.7.1.1.2.Software
14.7.1.1.2.1.Information/Data Management Software
14.7.1.1.2.2.Lab Automation Software
14.7.1.1.2.3.Others
14.7.1.1.3.Services
14.7.1.2.France In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
14.7.1.2.1.Immunoassay
14.7.1.2.2.Clinical Chemistry
14.7.1.2.3.Molecular Diagnostics
14.7.1.2.4.Hematology
14.7.1.2.5.Microbiology
14.7.1.2.6.Coagulation
14.7.1.2.7.Others
14.7.1.3.France In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
14.7.1.3.1.Infectious Disease
14.7.1.3.1.1.Hepatitis
14.7.1.3.1.2.Coronavirus Disease (COVID-19)
14.7.1.3.1.3.Others
14.7.1.3.2.Oncology
14.7.1.3.3.Diabetes
14.7.1.3.4.Cardiology
14.7.1.3.5.Gynecology and Women’s Health
14.7.1.3.6.Bone Health
14.7.1.3.7.Autoimmune Diseases
14.7.1.3.8.Others
14.7.1.4.France In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
14.7.1.4.1.Hospitals
14.7.1.4.2.Emergency Care Centers
14.7.1.4.3.Clinical Diagnostics Laboratories
14.7.1.4.4.Academic and Research Institutions
14.7.1.4.5.Home Care
14.7.1.4.6.Others
14.7.1.5.France In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
14.7.1.5.1.Direct
14.7.1.5.2.Indirect
14.7.2.The UK
14.7.2.1.The UK In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
14.7.2.1.1.Products
14.7.2.1.1.1.Systems and Instruments
14.7.2.1.1.1.1.Fully Automated Systems
14.7.2.1.1.1.2.Semi-Automated Systems
14.7.2.1.1.1.3.Others
14.7.2.1.1.2.Assays and Reagents
14.7.2.1.1.3.Calibrators and Control Materials
14.7.2.1.1.4.Reagent Kits
14.7.2.1.1.5.Others
14.7.2.1.2.Software
14.7.2.1.2.1.Information/Data Management Software
14.7.2.1.2.2.Lab Automation Software
14.7.2.1.2.3.Others
14.7.2.1.3.Services
14.7.2.2.The UK In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
14.7.2.2.1.Immunoassay
14.7.2.2.2.Clinical Chemistry
14.7.2.2.3.Molecular Diagnostics
14.7.2.2.4.Hematology
14.7.2.2.5.Microbiology
14.7.2.2.6.Coagulation
14.7.2.2.7.Others
14.7.2.3.The UK In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
14.7.2.3.1.Infectious Disease
14.7.2.3.1.1.Hepatitis
14.7.2.3.1.2.Coronavirus Disease (COVID-19)
14.7.2.3.1.3.Others
14.7.2.3.2.Oncology
14.7.2.3.3.Diabetes
14.7.2.3.4.Cardiology
14.7.2.3.5.Gynecology and Women’s Health
14.7.2.3.6.Bone Health
14.7.2.3.7.Autoimmune Diseases
14.7.2.3.8.Others
14.7.2.4.The UK In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
14.7.2.4.1.Hospitals
14.7.2.4.2.Emergency Care Centers
14.7.2.4.3.Clinical Diagnostics Laboratories
14.7.2.4.4.Academic and Research Institutions
14.7.2.4.5.Home Care
14.7.2.4.6.Others
14.7.2.5.The UK In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
14.7.2.5.1.Direct
14.7.2.5.2.Indirect
14.7.3.Spain
14.7.3.1.Spain In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
14.7.3.1.1.Products
14.7.3.1.1.1.Systems and Instruments
14.7.3.1.1.1.1.Fully Automated Systems
14.7.3.1.1.1.2.Semi-Automated Systems
14.7.3.1.1.1.3.Others
14.7.3.1.1.2.Assays and Reagents
14.7.3.1.1.3.Calibrators and Control Materials
14.7.3.1.1.4.Reagent Kits
14.7.3.1.1.5.Others
14.7.3.1.2.Software
14.7.3.1.2.1.Information/Data Management Software
14.7.3.1.2.2.Lab Automation Software
14.7.3.1.2.3.Others
14.7.3.1.3.Services
14.7.3.2.Spain In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
14.7.3.2.1.Immunoassay
14.7.3.2.2.Clinical Chemistry
14.7.3.2.3.Molecular Diagnostics
14.7.3.2.4.Hematology
14.7.3.2.5.Microbiology
14.7.3.2.6.Coagulation
14.7.3.2.7.Others
14.7.3.3.Spain In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
14.7.3.3.1.Infectious Disease
14.7.3.3.1.1.Hepatitis
14.7.3.3.1.2.Coronavirus Disease (COVID-19)
14.7.3.3.1.3.Others
14.7.3.3.2.Oncology
14.7.3.3.3.Diabetes
14.7.3.3.4.Cardiology
14.7.3.3.5.Gynecology and Women’s Health
14.7.3.3.6.Bone Health
14.7.3.3.7.Autoimmune Diseases
14.7.3.3.8.Others
14.7.3.4.Spain In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
14.7.3.4.1.Hospitals
14.7.3.4.2.Emergency Care Centers
14.7.3.4.3.Clinical Diagnostics Laboratories
14.7.3.4.4.Academic and Research Institutions
14.7.3.4.5.Home Care
14.7.3.4.6.Others
14.7.3.5.Spain In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
14.7.3.5.1.Direct
14.7.3.5.2.Indirect
14.7.4.Germany
14.7.4.1.Germany In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
14.7.4.1.1.Products
14.7.4.1.1.1.Systems and Instruments
14.7.4.1.1.1.1.Fully Automated Systems
14.7.4.1.1.1.2.Semi-Automated Systems
14.7.4.1.1.1.3.Others
14.7.4.1.1.2.Assays and Reagents
14.7.4.1.1.3.Calibrators and Control Materials
14.7.4.1.1.4.Reagent Kits
14.7.4.1.1.5.Others
14.7.4.1.2.Software
14.7.4.1.2.1.Information/Data Management Software
14.7.4.1.2.2.Lab Automation Software
14.7.4.1.2.3.Others
14.7.4.1.3.Services
14.7.4.2.Germany In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
14.7.4.2.1.Immunoassay
14.7.4.2.2.Clinical Chemistry
14.7.4.2.3.Molecular Diagnostics
14.7.4.2.4.Hematology
14.7.4.2.5.Microbiology
14.7.4.2.6.Coagulation
14.7.4.2.7.Others
14.7.4.3.Germany In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
14.7.4.3.1.Infectious Disease
14.7.4.3.1.1.Hepatitis
14.7.4.3.1.2.Coronavirus Disease (COVID-19)
14.7.4.3.1.3.Others
14.7.4.3.2.Oncology
14.7.4.3.3.Diabetes
14.7.4.3.4.Cardiology
14.7.4.3.5.Gynecology and Women’s Health
14.7.4.3.6.Bone Health
14.7.4.3.7.Autoimmune Diseases
14.7.4.3.8.Others
14.7.4.4.Germany In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
14.7.4.4.1.Hospitals
14.7.4.4.2.Emergency Care Centers
14.7.4.4.3.Clinical Diagnostics Laboratories
14.7.4.4.4.Academic and Research Institutions
14.7.4.4.5.Home Care
14.7.4.4.6.Others
14.7.4.5.Germany In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
14.7.4.5.1.Direct
14.7.4.5.2.Indirect
14.7.5.Italy
14.7.5.1.Italy In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
14.7.5.1.1.Products
14.7.5.1.1.1.Systems and Instruments
14.7.5.1.1.1.1.Fully Automated Systems
14.7.5.1.1.1.2.Semi-Automated Systems
14.7.5.1.1.1.3.Others
14.7.5.1.1.2.Assays and Reagents
14.7.5.1.1.3.Calibrators and Control Materials
14.7.5.1.1.4.Reagent Kits
14.7.5.1.1.5.Others
14.7.5.1.2.Software
14.7.5.1.2.1.Information/Data Management Software
14.7.5.1.2.2.Lab Automation Software
14.7.5.1.2.3.Others
14.7.5.1.3.Services
14.7.5.2.Italy In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
14.7.5.2.1.Immunoassay
14.7.5.2.2.Clinical Chemistry
14.7.5.2.3.Molecular Diagnostics
14.7.5.2.4.Hematology
14.7.5.2.5.Microbiology
14.7.5.2.6.Coagulation
14.7.5.2.7.Others
14.7.5.3.Italy In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
14.7.5.3.1.Infectious Disease
14.7.5.3.1.1.Hepatitis
14.7.5.3.1.2.Coronavirus Disease (COVID-19)
14.7.5.3.1.3.Others
14.7.5.3.2.Oncology
14.7.5.3.3.Diabetes
14.7.5.3.4.Cardiology
14.7.5.3.5.Gynecology and Women’s Health
14.7.5.3.6.Bone Health
14.7.5.3.7.Autoimmune Diseases
14.7.5.3.8.Others
14.7.5.4.Italy In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
14.7.5.4.1.Hospitals
14.7.5.4.2.Emergency Care Centers
14.7.5.4.3.Clinical Diagnostics Laboratories
14.7.5.4.4.Academic and Research Institutions
14.7.5.4.5.Home Care
14.7.5.4.6.Others
14.7.5.5.Italy In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
14.7.5.5.1.Direct
14.7.5.5.2.Indirect
14.7.6.Nordic Countries
14.7.6.1.Nordic Countries In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
14.7.6.1.1.Products
14.7.6.1.1.1.Systems and Instruments
14.7.6.1.1.1.1.Fully Automated Systems
14.7.6.1.1.1.2.Semi-Automated Systems
14.7.6.1.1.1.3.Others
14.7.6.1.1.2.Assays and Reagents
14.7.6.1.1.3.Calibrators and Control Materials
14.7.6.1.1.4.Reagent Kits
14.7.6.1.1.5.Others
14.7.6.1.2.Software
14.7.6.1.2.1.Information/Data Management Software
14.7.6.1.2.2.Lab Automation Software
14.7.6.1.2.3.Others
14.7.6.1.3.Services
14.7.6.2.Nordic Countries In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
14.7.6.2.1.Immunoassay
14.7.6.2.2.Clinical Chemistry
14.7.6.2.3.Molecular Diagnostics
14.7.6.2.4.Hematology
14.7.6.2.5.Microbiology
14.7.6.2.6.Coagulation
14.7.6.2.7.Others
14.7.6.3.Nordic Countries In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
14.7.6.3.1.Infectious Disease
14.7.6.3.1.1.Hepatitis
14.7.6.3.1.2.Coronavirus Disease (COVID-19)
14.7.6.3.1.3.Others
14.7.6.3.2.Oncology
14.7.6.3.3.Diabetes
14.7.6.3.4.Cardiology
14.7.6.3.5.Gynecology and Women’s Health
14.7.6.3.6.Bone Health
14.7.6.3.7.Autoimmune Diseases
14.7.6.3.8.Others
14.7.6.4.Nordic Countries In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
14.7.6.4.1.Hospitals
14.7.6.4.2.Emergency Care Centers
14.7.6.4.3.Clinical Diagnostics Laboratories
14.7.6.4.4.Academic and Research Institutions
14.7.6.4.5.Home Care
14.7.6.4.6.Others
14.7.6.5.Nordic Countries In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
14.7.6.5.1.Direct
14.7.6.5.2.Indirect
14.7.6.6.Nordic Countries In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Country
14.7.6.6.1.Denmark
14.7.6.6.2.Finland
14.7.6.6.3.Iceland
14.7.6.6.4.Sweden
14.7.6.6.5.Norway
14.7.7.Benelux Union
14.7.7.1.Benelux Union In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
14.7.7.1.1.Products
14.7.7.1.1.1.Systems and Instruments
14.7.7.1.1.1.1.Fully Automated Systems
14.7.7.1.1.1.2.Semi-Automated Systems
14.7.7.1.1.1.3.Others
14.7.7.1.1.2.Assays and Reagents
14.7.7.1.1.3.Calibrators and Control Materials
14.7.7.1.1.4.Reagent Kits
14.7.7.1.1.5.Others
14.7.7.1.2.Software
14.7.7.1.2.1.Information/Data Management Software
14.7.7.1.2.2.Lab Automation Software
14.7.7.1.2.3.Others
14.7.7.1.3.Services
14.7.7.2.Benelux Union In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
14.7.7.2.1.Immunoassay
14.7.7.2.2.Clinical Chemistry
14.7.7.2.3.Molecular Diagnostics
14.7.7.2.4.Hematology
14.7.7.2.5.Microbiology
14.7.7.2.6.Coagulation
14.7.7.2.7.Others
14.7.7.3.Benelux Union In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
14.7.7.3.1.Infectious Disease
14.7.7.3.1.1.Hepatitis
14.7.7.3.1.2.Coronavirus Disease (COVID-19)
14.7.7.3.1.3.Others
14.7.7.3.2.Oncology
14.7.7.3.3.Diabetes
14.7.7.3.4.Cardiology
14.7.7.3.5.Gynecology and Women’s Health
14.7.7.3.6.Bone Health
14.7.7.3.7.Autoimmune Diseases
14.7.7.3.8.Others
14.7.7.4.Benelux Union In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
14.7.7.4.1.Hospitals
14.7.7.4.2.Emergency Care Centers
14.7.7.4.3.Clinical Diagnostics Laboratories
14.7.7.4.4.Academic and Research Institutions
14.7.7.4.5.Home Care
14.7.7.4.6.Others
14.7.7.5.Benelux Union In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
14.7.7.5.1.Direct
14.7.7.5.2.Indirect
14.7.7.6.Benelux Union In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Country
14.7.7.6.1.Belgium
14.7.7.6.2.The Netherlands
14.7.7.6.3.Luxembourg
14.7.8.Rest of Europe
14.7.8.1.Rest of Europe In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
14.7.8.1.1.Products
14.7.8.1.1.1.Systems and Instruments
14.7.8.1.1.1.1.Fully Automated Systems
14.7.8.1.1.1.2.Semi-Automated Systems
14.7.8.1.1.1.3.Others
14.7.8.1.1.2.Assays and Reagents
14.7.8.1.1.3.Calibrators and Control Materials
14.7.8.1.1.4.Reagent Kits
14.7.8.1.1.5.Others
14.7.8.1.2.Software
14.7.8.1.2.1.Information/Data Management Software
14.7.8.1.2.2.Lab Automation Software
14.7.8.1.2.3.Others
14.7.8.1.3.Services
14.7.8.2.Rest of Europe In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
14.7.8.2.1.Immunoassay
14.7.8.2.2.Clinical Chemistry
14.7.8.2.3.Molecular Diagnostics
14.7.8.2.4.Hematology
14.7.8.2.5.Microbiology
14.7.8.2.6.Coagulation
14.7.8.2.7.Others
14.7.8.3.Rest of Europe In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
14.7.8.3.1.Infectious Disease
14.7.8.3.1.1.Hepatitis
14.7.8.3.1.2.Coronavirus Disease (COVID-19)
14.7.8.3.1.3.Others
14.7.8.3.2.Oncology
14.7.8.3.3.Diabetes
14.7.8.3.4.Cardiology
14.7.8.3.5.Gynecology and Women’s Health
14.7.8.3.6.Bone Health
14.7.8.3.7.Autoimmune Diseases
14.7.8.3.8.Others
14.7.8.4.Rest of Europe In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
14.7.8.4.1.Hospitals
14.7.8.4.2.Emergency Care Centers
14.7.8.4.3.Clinical Diagnostics Laboratories
14.7.8.4.4.Academic and Research Institutions
14.7.8.4.5.Home Care
14.7.8.4.6.Others
14.7.8.5.Rest of Europe In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
14.7.8.5.1.Direct
14.7.8.5.2.Indirect
14.8.Key Segment for Channeling Investments
14.8.1.By Country
14.8.2.By Offering
14.8.3.By Application
14.8.4.By Clinical Indication
14.8.5.By End Users
14.8.6.By Sales Channel
15.Asia Pacific In Vitro Diagnostics (IVD) Market Analysis and Forecasts, 2023 - 2031
15.1.Overview
15.1.1.Asia Pacific In Vitro Diagnostics (IVD) Market Revenue (US$ Mn)
15.2.Asia Pacific In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
15.2.1.Products
15.2.1.1.Systems and Instruments
15.2.1.1.1.Fully Automated Systems
15.2.1.1.2.Semi-Automated Systems
15.2.1.1.3.Others
15.2.1.2.Assays and Reagents
15.2.1.3.Calibrators and Control Materials
15.2.1.4.Reagent Kits
15.2.1.5.Others
15.2.2.Software
15.2.2.1.Information/Data Management Software
15.2.2.2.Lab Automation Software
15.2.2.3.Others
15.2.3.Services
15.3.Asia Pacific In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
15.3.1.Immunoassay
15.3.2.Clinical Chemistry
15.3.3.Molecular Diagnostics
15.3.4.Hematology
15.3.5.Microbiology
15.3.6.Coagulation
15.3.7.Others
15.4.Asia Pacific In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
15.4.1.Infectious Disease
15.4.1.1.Hepatitis
15.4.1.2.Coronavirus Disease (COVID-19)
15.4.1.3.Others
15.4.2.Oncology
15.4.3.Diabetes
15.4.4.Cardiology
15.4.5.Gynecology and Women’s Health
15.4.6.Bone Health
15.4.7.Autoimmune Diseases
15.4.8.Others
15.5.Asia Pacific In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
15.5.1.Hospitals
15.5.2.Emergency Care Centers
15.5.3.Clinical Diagnostics Laboratories
15.5.4.Academic and Research Institutions
15.5.5.Home Care
15.5.6.Others
15.6.Asia Pacific In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
15.6.1.Direct
15.6.2.Indirect
15.7.Asia Pacific In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Country
15.7.1.China
15.7.1.1.China In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
15.7.1.1.1.Products
15.7.1.1.1.1.Systems and Instruments
15.7.1.1.1.1.1.Fully Automated Systems
15.7.1.1.1.1.2.Semi-Automated Systems
15.7.1.1.1.1.3.Others
15.7.1.1.1.2.Assays and Reagents
15.7.1.1.1.3.Calibrators and Control Materials
15.7.1.1.1.4.Reagent Kits
15.7.1.1.1.5.Others
15.7.1.1.2.Software
15.7.1.1.2.1.Information/Data Management Software
15.7.1.1.2.2.Lab Automation Software
15.7.1.1.2.3.Others
15.7.1.1.3.Services
15.7.1.2.China In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
15.7.1.2.1.Immunoassay
15.7.1.2.2.Clinical Chemistry
15.7.1.2.3.Molecular Diagnostics
15.7.1.2.4.Hematology
15.7.1.2.5.Microbiology
15.7.1.2.6.Coagulation
15.7.1.2.7.Others
15.7.1.3.China In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
15.7.1.3.1.Infectious Disease
15.7.1.3.1.1.Hepatitis
15.7.1.3.1.2.Coronavirus Disease (COVID-19)
15.7.1.3.1.3.Others
15.7.1.3.2.Oncology
15.7.1.3.3.Diabetes
15.7.1.3.4.Cardiology
15.7.1.3.5.Gynecology and Women’s Health
15.7.1.3.6.Bone Health
15.7.1.3.7.Autoimmune Diseases
15.7.1.3.8.Others
15.7.1.4.China In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
15.7.1.4.1.Hospitals
15.7.1.4.2.Emergency Care Centers
15.7.1.4.3.Clinical Diagnostics Laboratories
15.7.1.4.4.Academic and Research Institutions
15.7.1.4.5.Home Care
15.7.1.4.6.Others
15.7.1.5.China In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
15.7.1.5.1.Direct
15.7.1.5.2.Indirect
15.7.2.Japan
15.7.2.1.Japan In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
15.7.2.1.1.Products
15.7.2.1.1.1.Systems and Instruments
15.7.2.1.1.1.1.Fully Automated Systems
15.7.2.1.1.1.2.Semi-Automated Systems
15.7.2.1.1.1.3.Others
15.7.2.1.1.2.Assays and Reagents
15.7.2.1.1.3.Calibrators and Control Materials
15.7.2.1.1.4.Reagent Kits
15.7.2.1.1.5.Others
15.7.2.1.2.Software
15.7.2.1.2.1.Information/Data Management Software
15.7.2.1.2.2.Lab Automation Software
15.7.2.1.2.3.Others
15.7.2.1.3.Services
15.7.2.2.Japan In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
15.7.2.2.1.Immunoassay
15.7.2.2.2.Clinical Chemistry
15.7.2.2.3.Molecular Diagnostics
15.7.2.2.4.Hematology
15.7.2.2.5.Microbiology
15.7.2.2.6.Coagulation
15.7.2.2.7.Others
15.7.2.3.Japan In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
15.7.2.3.1.Infectious Disease
15.7.2.3.1.1.Hepatitis
15.7.2.3.1.2.Coronavirus Disease (COVID-19)
15.7.2.3.1.3.Others
15.7.2.3.2.Oncology
15.7.2.3.3.Diabetes
15.7.2.3.4.Cardiology
15.7.2.3.5.Gynecology and Women’s Health
15.7.2.3.6.Bone Health
15.7.2.3.7.Autoimmune Diseases
15.7.2.3.8.Others
15.7.2.4.Japan In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
15.7.2.4.1.Hospitals
15.7.2.4.2.Emergency Care Centers
15.7.2.4.3.Clinical Diagnostics Laboratories
15.7.2.4.4.Academic and Research Institutions
15.7.2.4.5.Home Care
15.7.2.4.6.Others
15.7.2.5.Japan In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
15.7.2.5.1.Direct
15.7.2.5.2.Indirect
15.7.3.India
15.7.3.1.India In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
15.7.3.1.1.Products
15.7.3.1.1.1.Systems and Instruments
15.7.3.1.1.1.1.Fully Automated Systems
15.7.3.1.1.1.2.Semi-Automated Systems
15.7.3.1.1.1.3.Others
15.7.3.1.1.2.Assays and Reagents
15.7.3.1.1.3.Calibrators and Control Materials
15.7.3.1.1.4.Reagent Kits
15.7.3.1.1.5.Others
15.7.3.1.2.Software
15.7.3.1.2.1.Information/Data Management Software
15.7.3.1.2.2.Lab Automation Software
15.7.3.1.2.3.Others
15.7.3.1.3.Services
15.7.3.2.India In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
15.7.3.2.1.Immunoassay
15.7.3.2.2.Clinical Chemistry
15.7.3.2.3.Molecular Diagnostics
15.7.3.2.4.Hematology
15.7.3.2.5.Microbiology
15.7.3.2.6.Coagulation
15.7.3.2.7.Others
15.7.3.3.India In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
15.7.3.3.1.Infectious Disease
15.7.3.3.1.1.Hepatitis
15.7.3.3.1.2.Coronavirus Disease (COVID-19)
15.7.3.3.1.3.Others
15.7.3.3.2.Oncology
15.7.3.3.3.Diabetes
15.7.3.3.4.Cardiology
15.7.3.3.5.Gynecology and Women’s Health
15.7.3.3.6.Bone Health
15.7.3.3.7.Autoimmune Diseases
15.7.3.3.8.Others
15.7.3.4.India In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
15.7.3.4.1.Hospitals
15.7.3.4.2.Emergency Care Centers
15.7.3.4.3.Clinical Diagnostics Laboratories
15.7.3.4.4.Academic and Research Institutions
15.7.3.4.5.Home Care
15.7.3.4.6.Others
15.7.3.5.India In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
15.7.3.5.1.Direct
15.7.3.5.2.Indirect
15.7.4.New Zealand
15.7.4.1.New Zealand In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
15.7.4.1.1.Products
15.7.4.1.1.1.Systems and Instruments
15.7.4.1.1.1.1.Fully Automated Systems
15.7.4.1.1.1.2.Semi-Automated Systems
15.7.4.1.1.1.3.Others
15.7.4.1.1.2.Assays and Reagents
15.7.4.1.1.3.Calibrators and Control Materials
15.7.4.1.1.4.Reagent Kits
15.7.4.1.1.5.Others
15.7.4.1.2.Software
15.7.4.1.2.1.Information/Data Management Software
15.7.4.1.2.2.Lab Automation Software
15.7.4.1.2.3.Others
15.7.4.1.3.Services
15.7.4.2.New Zealand In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
15.7.4.2.1.Immunoassay
15.7.4.2.2.Clinical Chemistry
15.7.4.2.3.Molecular Diagnostics
15.7.4.2.4.Hematology
15.7.4.2.5.Microbiology
15.7.4.2.6.Coagulation
15.7.4.2.7.Others
15.7.4.3.New Zealand In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
15.7.4.3.1.Infectious Disease
15.7.4.3.1.1.Hepatitis
15.7.4.3.1.2.Coronavirus Disease (COVID-19)
15.7.4.3.1.3.Others
15.7.4.3.2.Oncology
15.7.4.3.3.Diabetes
15.7.4.3.4.Cardiology
15.7.4.3.5.Gynecology and Women’s Health
15.7.4.3.6.Bone Health
15.7.4.3.7.Autoimmune Diseases
15.7.4.3.8.Others
15.7.4.4.New Zealand In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
15.7.4.4.1.Hospitals
15.7.4.4.2.Emergency Care Centers
15.7.4.4.3.Clinical Diagnostics Laboratories
15.7.4.4.4.Academic and Research Institutions
15.7.4.4.5.Home Care
15.7.4.4.6.Others
15.7.4.5.New Zealand In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
15.7.4.5.1.Direct
15.7.4.5.2.Indirect
15.7.5.Australia
15.7.5.1.Australia In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
15.7.5.1.1.Products
15.7.5.1.1.1.Systems and Instruments
15.7.5.1.1.1.1.Fully Automated Systems
15.7.5.1.1.1.2.Semi-Automated Systems
15.7.5.1.1.1.3.Others
15.7.5.1.1.2.Assays and Reagents
15.7.5.1.1.3.Calibrators and Control Materials
15.7.5.1.1.4.Reagent Kits
15.7.5.1.1.5.Others
15.7.5.1.2.Software
15.7.5.1.2.1.Information/Data Management Software
15.7.5.1.2.2.Lab Automation Software
15.7.5.1.2.3.Others
15.7.5.1.3.Services
15.7.5.2.Australia In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
15.7.5.2.1.Immunoassay
15.7.5.2.2.Clinical Chemistry
15.7.5.2.3.Molecular Diagnostics
15.7.5.2.4.Hematology
15.7.5.2.5.Microbiology
15.7.5.2.6.Coagulation
15.7.5.2.7.Others
15.7.5.3.Australia In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
15.7.5.3.1.Infectious Disease
15.7.5.3.1.1.Hepatitis
15.7.5.3.1.2.Coronavirus Disease (COVID-19)
15.7.5.3.1.3.Others
15.7.5.3.2.Oncology
15.7.5.3.3.Diabetes
15.7.5.3.4.Cardiology
15.7.5.3.5.Gynecology and Women’s Health
15.7.5.3.6.Bone Health
15.7.5.3.7.Autoimmune Diseases
15.7.5.3.8.Others
15.7.5.4.Australia In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
15.7.5.4.1.Hospitals
15.7.5.4.2.Emergency Care Centers
15.7.5.4.3.Clinical Diagnostics Laboratories
15.7.5.4.4.Academic and Research Institutions
15.7.5.4.5.Home Care
15.7.5.4.6.Others
15.7.5.5.Australia In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
15.7.5.5.1.Direct
15.7.5.5.2.Indirect
15.7.6.South Korea
15.7.6.1.South Korea In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
15.7.6.1.1.Products
15.7.6.1.1.1.Systems and Instruments
15.7.6.1.1.1.1.Fully Automated Systems
15.7.6.1.1.1.2.Semi-Automated Systems
15.7.6.1.1.1.3.Others
15.7.6.1.1.2.Assays and Reagents
15.7.6.1.1.3.Calibrators and Control Materials
15.7.6.1.1.4.Reagent Kits
15.7.6.1.1.5.Others
15.7.6.1.2.Software
15.7.6.1.2.1.Information/Data Management Software
15.7.6.1.2.2.Lab Automation Software
15.7.6.1.2.3.Others
15.7.6.1.3.Services
15.7.6.2.South Korea In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
15.7.6.2.1.Immunoassay
15.7.6.2.2.Clinical Chemistry
15.7.6.2.3.Molecular Diagnostics
15.7.6.2.4.Hematology
15.7.6.2.5.Microbiology
15.7.6.2.6.Coagulation
15.7.6.2.7.Others
15.7.6.3.South Korea In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
15.7.6.3.1.Infectious Disease
15.7.6.3.1.1.Hepatitis
15.7.6.3.1.2.Coronavirus Disease (COVID-19)
15.7.6.3.1.3.Others
15.7.6.3.2.Oncology
15.7.6.3.3.Diabetes
15.7.6.3.4.Cardiology
15.7.6.3.5.Gynecology and Women’s Health
15.7.6.3.6.Bone Health
15.7.6.3.7.Autoimmune Diseases
15.7.6.3.8.Others
15.7.6.4.South Korea In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
15.7.6.4.1.Hospitals
15.7.6.4.2.Emergency Care Centers
15.7.6.4.3.Clinical Diagnostics Laboratories
15.7.6.4.4.Academic and Research Institutions
15.7.6.4.5.Home Care
15.7.6.4.6.Others
15.7.6.5.South Korea In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
15.7.6.5.1.Direct
15.7.6.5.2.Indirect
15.7.7.Southeast Asia
15.7.7.1.Southeast Asia In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
15.7.7.1.1.Products
15.7.7.1.1.1.Systems and Instruments
15.7.7.1.1.1.1.Fully Automated Systems
15.7.7.1.1.1.2.Semi-Automated Systems
15.7.7.1.1.1.3.Others
15.7.7.1.1.2.Assays and Reagents
15.7.7.1.1.3.Calibrators and Control Materials
15.7.7.1.1.4.Reagent Kits
15.7.7.1.1.5.Others
15.7.7.1.2.Software
15.7.7.1.2.1.Information/Data Management Software
15.7.7.1.2.2.Lab Automation Software
15.7.7.1.2.3.Others
15.7.7.1.3.Services
15.7.7.2.Southeast Asia In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
15.7.7.2.1.Immunoassay
15.7.7.2.2.Clinical Chemistry
15.7.7.2.3.Molecular Diagnostics
15.7.7.2.4.Hematology
15.7.7.2.5.Microbiology
15.7.7.2.6.Coagulation
15.7.7.2.7.Others
15.7.7.3.Southeast Asia In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
15.7.7.3.1.Infectious Disease
15.7.7.3.1.1.Hepatitis
15.7.7.3.1.2.Coronavirus Disease (COVID-19)
15.7.7.3.1.3.Others
15.7.7.3.2.Oncology
15.7.7.3.3.Diabetes
15.7.7.3.4.Cardiology
15.7.7.3.5.Gynecology and Women’s Health
15.7.7.3.6.Bone Health
15.7.7.3.7.Autoimmune Diseases
15.7.7.3.8.Others
15.7.7.4.Southeast Asia In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
15.7.7.4.1.Hospitals
15.7.7.4.2.Emergency Care Centers
15.7.7.4.3.Clinical Diagnostics Laboratories
15.7.7.4.4.Academic and Research Institutions
15.7.7.4.5.Home Care
15.7.7.4.6.Others
15.7.7.5.Southeast Asia In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
15.7.7.5.1.Direct
15.7.7.5.2.Indirect
15.7.7.6.Southeast Asia In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Country
15.7.7.6.1.Indonesia
15.7.7.6.2.Thailand
15.7.7.6.3.Malaysia
15.7.7.6.4.Singapore
15.7.7.6.5.Rest of Southeast Asia
15.7.8.Rest of Asia Pacific
15.7.8.1.Rest of Asia Pacific In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
15.7.8.1.1.Products
15.7.8.1.1.1.Systems and Instruments
15.7.8.1.1.1.1.Fully Automated Systems
15.7.8.1.1.1.2.Semi-Automated Systems
15.7.8.1.1.1.3.Others
15.7.8.1.1.2.Assays and Reagents
15.7.8.1.1.3.Calibrators and Control Materials
15.7.8.1.1.4.Reagent Kits
15.7.8.1.1.5.Others
15.7.8.1.2.Software
15.7.8.1.2.1.Information/Data Management Software
15.7.8.1.2.2.Lab Automation Software
15.7.8.1.2.3.Others
15.7.8.1.3.Services
15.7.8.2.Rest of Asia Pacific In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
15.7.8.2.1.Immunoassay
15.7.8.2.2.Clinical Chemistry
15.7.8.2.3.Molecular Diagnostics
15.7.8.2.4.Hematology
15.7.8.2.5.Microbiology
15.7.8.2.6.Coagulation
15.7.8.2.7.Others
15.7.8.3.Rest of Asia Pacific In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
15.7.8.3.1.Infectious Disease
15.7.8.3.1.1.Hepatitis
15.7.8.3.1.2.Coronavirus Disease (COVID-19)
15.7.8.3.1.3.Others
15.7.8.3.2.Oncology
15.7.8.3.3.Diabetes
15.7.8.3.4.Cardiology
15.7.8.3.5.Gynecology and Women’s Health
15.7.8.3.6.Bone Health
15.7.8.3.7.Autoimmune Diseases
15.7.8.3.8.Others
15.7.8.4.Rest of Asia Pacific In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
15.7.8.4.1.Hospitals
15.7.8.4.2.Emergency Care Centers
15.7.8.4.3.Clinical Diagnostics Laboratories
15.7.8.4.4.Academic and Research Institutions
15.7.8.4.5.Home Care
15.7.8.4.6.Others
15.7.8.5.Rest of Asia Pacific In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
15.7.8.5.1.Direct
15.7.8.5.2.Indirect
15.8.Key Segment for Channeling Investments
15.8.1.By Country
15.8.2.By Offering
15.8.3.By Application
15.8.4.By Clinical Indication
15.8.5.By End Users
15.8.6.By Sales Channel
16.Middle East and Africa In Vitro Diagnostics (IVD) Market Analysis and Forecasts, 2023 - 2031
16.1.Overview
16.1.1.Middle East and Africa In Vitro Diagnostics (IVD) Market Revenue (US$ Mn)
16.2.Middle East and Africa In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
16.2.1.Products
16.2.1.1.Systems and Instruments
16.2.1.1.1.Fully Automated Systems
16.2.1.1.2.Semi-Automated Systems
16.2.1.1.3.Others
16.2.1.2.Assays and Reagents
16.2.1.3.Calibrators and Control Materials
16.2.1.4.Reagent Kits
16.2.1.5.Others
16.2.2.Software
16.2.2.1.Information/Data Management Software
16.2.2.2.Lab Automation Software
16.2.2.3.Others
16.2.3.Services
16.3.Middle East and Africa In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
16.3.1.Immunoassay
16.3.2.Clinical Chemistry
16.3.3.Molecular Diagnostics
16.3.4.Hematology
16.3.5.Microbiology
16.3.6.Coagulation
16.3.7.Others
16.4.Middle East and Africa In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
16.4.1.Infectious Disease
16.4.1.1.Hepatitis
16.4.1.2.Coronavirus Disease (COVID-19)
16.4.1.3.Others
16.4.2.Oncology
16.4.3.Diabetes
16.4.4.Cardiology
16.4.5.Gynecology and Women’s Health
16.4.6.Bone Health
16.4.7.Autoimmune Diseases
16.4.8.Others
16.5.Middle East and Africa In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
16.5.1.Hospitals
16.5.2.Emergency Care Centers
16.5.3.Clinical Diagnostics Laboratories
16.5.4.Academic and Research Institutions
16.5.5.Home Care
16.5.6.Others
16.6.Middle East and Africa In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
16.6.1.Direct
16.6.2.Indirect
16.7.Middle East and Africa In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Country
16.7.1.Saudi Arabia
16.7.1.1.Saudi Arabia In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
16.7.1.1.1.Products
16.7.1.1.1.1.Systems and Instruments
16.7.1.1.1.1.1.Fully Automated Systems
16.7.1.1.1.1.2.Semi-Automated Systems
16.7.1.1.1.1.3.Others
16.7.1.1.1.2.Assays and Reagents
16.7.1.1.1.3.Calibrators and Control Materials
16.7.1.1.1.4.Reagent Kits
16.7.1.1.1.5.Others
16.7.1.1.2.Software
16.7.1.1.2.1.Information/Data Management Software
16.7.1.1.2.2.Lab Automation Software
16.7.1.1.2.3.Others
16.7.1.1.3.Services
16.7.1.2.Saudi Arabia In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
16.7.1.2.1.Immunoassay
16.7.1.2.2.Clinical Chemistry
16.7.1.2.3.Molecular Diagnostics
16.7.1.2.4.Hematology
16.7.1.2.5.Microbiology
16.7.1.2.6.Coagulation
16.7.1.2.7.Others
16.7.1.3.Saudi Arabia In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
16.7.1.3.1.Infectious Disease
16.7.1.3.1.1.Hepatitis
16.7.1.3.1.2.Coronavirus Disease (COVID-19)
16.7.1.3.1.3.Others
16.7.1.3.2.Oncology
16.7.1.3.3.Diabetes
16.7.1.3.4.Cardiology
16.7.1.3.5.Gynecology and Women’s Health
16.7.1.3.6.Bone Health
16.7.1.3.7.Autoimmune Diseases
16.7.1.3.8.Others
16.7.1.4.Saudi Arabia In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
16.7.1.4.1.Hospitals
16.7.1.4.2.Emergency Care Centers
16.7.1.4.3.Clinical Diagnostics Laboratories
16.7.1.4.4.Academic and Research Institutions
16.7.1.4.5.Home Care
16.7.1.4.6.Others
16.7.1.5.Saudi Arabia In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
16.7.1.5.1.Direct
16.7.1.5.2.Indirect
16.7.2.UAE
16.7.2.1.UAE In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
16.7.2.1.1.Products
16.7.2.1.1.1.Systems and Instruments
16.7.2.1.1.1.1.Fully Automated Systems
16.7.2.1.1.1.2.Semi-Automated Systems
16.7.2.1.1.1.3.Others
16.7.2.1.1.2.Assays and Reagents
16.7.2.1.1.3.Calibrators and Control Materials
16.7.2.1.1.4.Reagent Kits
16.7.2.1.1.5.Others
16.7.2.1.2.Software
16.7.2.1.2.1.Information/Data Management Software
16.7.2.1.2.2.Lab Automation Software
16.7.2.1.2.3.Others
16.7.2.1.3.Services
16.7.2.2.UAE In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
16.7.2.2.1.Immunoassay
16.7.2.2.2.Clinical Chemistry
16.7.2.2.3.Molecular Diagnostics
16.7.2.2.4.Hematology
16.7.2.2.5.Microbiology
16.7.2.2.6.Coagulation
16.7.2.2.7.Others
16.7.2.3.UAE In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
16.7.2.3.1.Infectious Disease
16.7.2.3.1.1.Hepatitis
16.7.2.3.1.2.Coronavirus Disease (COVID-19)
16.7.2.3.1.3.Others
16.7.2.3.2.Oncology
16.7.2.3.3.Diabetes
16.7.2.3.4.Cardiology
16.7.2.3.5.Gynecology and Women’s Health
16.7.2.3.6.Bone Health
16.7.2.3.7.Autoimmune Diseases
16.7.2.3.8.Others
16.7.2.4.UAE In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
16.7.2.4.1.Hospitals
16.7.2.4.2.Emergency Care Centers
16.7.2.4.3.Clinical Diagnostics Laboratories
16.7.2.4.4.Academic and Research Institutions
16.7.2.4.5.Home Care
16.7.2.4.6.Others
16.7.2.5.UAE In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
16.7.2.5.1.Direct
16.7.2.5.2.Indirect
16.7.3.Egypt
16.7.3.1.Egypt In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
16.7.3.1.1.Products
16.7.3.1.1.1.Systems and Instruments
16.7.3.1.1.1.1.Fully Automated Systems
16.7.3.1.1.1.2.Semi-Automated Systems
16.7.3.1.1.1.3.Others
16.7.3.1.1.2.Assays and Reagents
16.7.3.1.1.3.Calibrators and Control Materials
16.7.3.1.1.4.Reagent Kits
16.7.3.1.1.5.Others
16.7.3.1.2.Software
16.7.3.1.2.1.Information/Data Management Software
16.7.3.1.2.2.Lab Automation Software
16.7.3.1.2.3.Others
16.7.3.1.3.Services
16.7.3.2.Egypt In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
16.7.3.2.1.Immunoassay
16.7.3.2.2.Clinical Chemistry
16.7.3.2.3.Molecular Diagnostics
16.7.3.2.4.Hematology
16.7.3.2.5.Microbiology
16.7.3.2.6.Coagulation
16.7.3.2.7.Others
16.7.3.3.Egypt In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
16.7.3.3.1.Infectious Disease
16.7.3.3.1.1.Hepatitis
16.7.3.3.1.2.Coronavirus Disease (COVID-19)
16.7.3.3.1.3.Others
16.7.3.3.2.Oncology
16.7.3.3.3.Diabetes
16.7.3.3.4.Cardiology
16.7.3.3.5.Gynecology and Women’s Health
16.7.3.3.6.Bone Health
16.7.3.3.7.Autoimmune Diseases
16.7.3.3.8.Others
16.7.3.4.Egypt In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
16.7.3.4.1.Hospitals
16.7.3.4.2.Emergency Care Centers
16.7.3.4.3.Clinical Diagnostics Laboratories
16.7.3.4.4.Academic and Research Institutions
16.7.3.4.5.Home Care
16.7.3.4.6.Others
16.7.3.5.Egypt In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
16.7.3.5.1.Direct
16.7.3.5.2.Indirect
16.7.4.Kuwait
16.7.4.1.Kuwait In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
16.7.4.1.1.Products
16.7.4.1.1.1.Systems and Instruments
16.7.4.1.1.1.1.Fully Automated Systems
16.7.4.1.1.1.2.Semi-Automated Systems
16.7.4.1.1.1.3.Others
16.7.4.1.1.2.Assays and Reagents
16.7.4.1.1.3.Calibrators and Control Materials
16.7.4.1.1.4.Reagent Kits
16.7.4.1.1.5.Others
16.7.4.1.2.Software
16.7.4.1.2.1.Information/Data Management Software
16.7.4.1.2.2.Lab Automation Software
16.7.4.1.2.3.Others
16.7.4.1.3.Services
16.7.4.2.Kuwait In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
16.7.4.2.1.Immunoassay
16.7.4.2.2.Clinical Chemistry
16.7.4.2.3.Molecular Diagnostics
16.7.4.2.4.Hematology
16.7.4.2.5.Microbiology
16.7.4.2.6.Coagulation
16.7.4.2.7.Others
16.7.4.3.Kuwait In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
16.7.4.3.1.Infectious Disease
16.7.4.3.1.1.Hepatitis
16.7.4.3.1.2.Coronavirus Disease (COVID-19)
16.7.4.3.1.3.Others
16.7.4.3.2.Oncology
16.7.4.3.3.Diabetes
16.7.4.3.4.Cardiology
16.7.4.3.5.Gynecology and Women’s Health
16.7.4.3.6.Bone Health
16.7.4.3.7.Autoimmune Diseases
16.7.4.3.8.Others
16.7.4.4.Kuwait In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
16.7.4.4.1.Hospitals
16.7.4.4.2.Emergency Care Centers
16.7.4.4.3.Clinical Diagnostics Laboratories
16.7.4.4.4.Academic and Research Institutions
16.7.4.4.5.Home Care
16.7.4.4.6.Others
16.7.4.5.Kuwait In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
16.7.4.5.1.Direct
16.7.4.5.2.Indirect
16.7.5.South Africa
16.7.5.1.South Africa In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
16.7.5.1.1.Products
16.7.5.1.1.1.Systems and Instruments
16.7.5.1.1.1.1.Fully Automated Systems
16.7.5.1.1.1.2.Semi-Automated Systems
16.7.5.1.1.1.3.Others
16.7.5.1.1.2.Assays and Reagents
16.7.5.1.1.3.Calibrators and Control Materials
16.7.5.1.1.4.Reagent Kits
16.7.5.1.1.5.Others
16.7.5.1.2.Software
16.7.5.1.2.1.Information/Data Management Software
16.7.5.1.2.2.Lab Automation Software
16.7.5.1.2.3.Others
16.7.5.1.3.Services
16.7.5.2.South Africa In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
16.7.5.2.1.Immunoassay
16.7.5.2.2.Clinical Chemistry
16.7.5.2.3.Molecular Diagnostics
16.7.5.2.4.Hematology
16.7.5.2.5.Microbiology
16.7.5.2.6.Coagulation
16.7.5.2.7.Others
16.7.5.3.South Africa In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
16.7.5.3.1.Infectious Disease
16.7.5.3.1.1.Hepatitis
16.7.5.3.1.2.Coronavirus Disease (COVID-19)
16.7.5.3.1.3.Others
16.7.5.3.2.Oncology
16.7.5.3.3.Diabetes
16.7.5.3.4.Cardiology
16.7.5.3.5.Gynecology and Women’s Health
16.7.5.3.6.Bone Health
16.7.5.3.7.Autoimmune Diseases
16.7.5.3.8.Others
16.7.5.4.South Africa In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
16.7.5.4.1.Hospitals
16.7.5.4.2.Emergency Care Centers
16.7.5.4.3.Clinical Diagnostics Laboratories
16.7.5.4.4.Academic and Research Institutions
16.7.5.4.5.Home Care
16.7.5.4.6.Others
16.7.5.5.South Africa In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
16.7.5.5.1.Direct
16.7.5.5.2.Indirect
16.7.6.Rest of Middle East & Africa
16.7.6.1.Rest of Middle East & Africa In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
16.7.6.1.1.Products
16.7.6.1.1.1.Systems and Instruments
16.7.6.1.1.1.1.Fully Automated Systems
16.7.6.1.1.1.2.Semi-Automated Systems
16.7.6.1.1.1.3.Others
16.7.6.1.1.2.Assays and Reagents
16.7.6.1.1.3.Calibrators and Control Materials
16.7.6.1.1.4.Reagent Kits
16.7.6.1.1.5.Others
16.7.6.1.2.Software
16.7.6.1.2.1.Information/Data Management Software
16.7.6.1.2.2.Lab Automation Software
16.7.6.1.2.3.Others
16.7.6.1.3.Services
16.7.6.2.Rest of Middle East & Africa In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
16.7.6.2.1.Immunoassay
16.7.6.2.2.Clinical Chemistry
16.7.6.2.3.Molecular Diagnostics
16.7.6.2.4.Hematology
16.7.6.2.5.Microbiology
16.7.6.2.6.Coagulation
16.7.6.2.7.Others
16.7.6.3.Rest of Middle East & Africa In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
16.7.6.3.1.Infectious Disease
16.7.6.3.1.1.Hepatitis
16.7.6.3.1.2.Coronavirus Disease (COVID-19)
16.7.6.3.1.3.Others
16.7.6.3.2.Oncology
16.7.6.3.3.Diabetes
16.7.6.3.4.Cardiology
16.7.6.3.5.Gynecology and Women’s Health
16.7.6.3.6.Bone Health
16.7.6.3.7.Autoimmune Diseases
16.7.6.3.8.Others
16.7.6.4.Rest of Middle East & Africa In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
16.7.6.4.1.Hospitals
16.7.6.4.2.Emergency Care Centers
16.7.6.4.3.Clinical Diagnostics Laboratories
16.7.6.4.4.Academic and Research Institutions
16.7.6.4.5.Home Care
16.7.6.4.6.Others
16.7.6.5.Rest of Middle East & Africa In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
16.7.6.5.1.Direct
16.7.6.5.2.Indirect
16.8.Key Segment for Channeling Investments
16.8.1.By Country
16.8.2.By Offering
16.8.3.By Application
16.8.4.By Clinical Indication
16.8.5.By End Users
16.8.6.By Sales Channel
17.Latin America In Vitro Diagnostics (IVD) Market Analysis and Forecasts, 2023 - 2031
17.1.Overview
17.1.1.Latin America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn)
17.2.Latin America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
17.2.1.Products
17.2.1.1.Systems and Instruments
17.2.1.1.1.Fully Automated Systems
17.2.1.1.2.Semi-Automated Systems
17.2.1.1.3.Others
17.2.1.2.Assays and Reagents
17.2.1.3.Calibrators and Control Materials
17.2.1.4.Reagent Kits
17.2.1.5.Others
17.2.2.Software
17.2.2.1.Information/Data Management Software
17.2.2.2.Lab Automation Software
17.2.2.3.Others
17.2.3.Services
17.3.Latin America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
17.3.1.Immunoassay
17.3.2.Clinical Chemistry
17.3.3.Molecular Diagnostics
17.3.4.Hematology
17.3.5.Microbiology
17.3.6.Coagulation
17.3.7.Others
17.4.Latin America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
17.4.1.Infectious Disease
17.4.1.1.Hepatitis
17.4.1.2.Coronavirus Disease (COVID-19)
17.4.1.3.Others
17.4.2.Oncology
17.4.3.Diabetes
17.4.4.Cardiology
17.4.5.Gynecology and Women’s Health
17.4.6.Bone Health
17.4.7.Autoimmune Diseases
17.4.8.Others
17.5.Latin America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
17.5.1.Hospitals
17.5.2.Emergency Care Centers
17.5.3.Clinical Diagnostics Laboratories
17.5.4.Academic and Research Institutions
17.5.5.Home Care
17.5.6.Others
17.6.Latin America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
17.6.1.Direct
17.6.2.Indirect
17.7.Latin America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Country
17.7.1.Brazil
17.7.1.1.Brazil In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
17.7.1.1.1.Products
17.7.1.1.1.1.Systems and Instruments
17.7.1.1.1.1.1.Fully Automated Systems
17.7.1.1.1.1.2.Semi-Automated Systems
17.7.1.1.1.1.3.Others
17.7.1.1.1.2.Assays and Reagents
17.7.1.1.1.3.Calibrators and Control Materials
17.7.1.1.1.4.Reagent Kits
17.7.1.1.1.5.Others
17.7.1.1.2.Software
17.7.1.1.2.1.Information/Data Management Software
17.7.1.1.2.2.Lab Automation Software
17.7.1.1.2.3.Others
17.7.1.1.3.Services
17.7.1.2.Brazil In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
17.7.1.2.1.Immunoassay
17.7.1.2.2.Clinical Chemistry
17.7.1.2.3.Molecular Diagnostics
17.7.1.2.4.Hematology
17.7.1.2.5.Microbiology
17.7.1.2.6.Coagulation
17.7.1.2.7.Others
17.7.1.3.Brazil In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
17.7.1.3.1.Infectious Disease
17.7.1.3.1.1.Hepatitis
17.7.1.3.1.2.Coronavirus Disease (COVID-19)
17.7.1.3.1.3.Others
17.7.1.3.2.Oncology
17.7.1.3.3.Diabetes
17.7.1.3.4.Cardiology
17.7.1.3.5.Gynecology and Women’s Health
17.7.1.3.6.Bone Health
17.7.1.3.7.Autoimmune Diseases
17.7.1.3.8.Others
17.7.1.4.Brazil In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
17.7.1.4.1.Hospitals
17.7.1.4.2.Emergency Care Centers
17.7.1.4.3.Clinical Diagnostics Laboratories
17.7.1.4.4.Academic and Research Institutions
17.7.1.4.5.Home Care
17.7.1.4.6.Others
17.7.1.5.Brazil In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
17.7.1.5.1.Direct
17.7.1.5.2.Indirect
17.7.2.Argentina
17.7.2.1.Argentina In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
17.7.2.1.1.Products
17.7.2.1.1.1.Systems and Instruments
17.7.2.1.1.1.1.Fully Automated Systems
17.7.2.1.1.1.2.Semi-Automated Systems
17.7.2.1.1.1.3.Others
17.7.2.1.1.2.Assays and Reagents
17.7.2.1.1.3.Calibrators and Control Materials
17.7.2.1.1.4.Reagent Kits
17.7.2.1.1.5.Others
17.7.2.1.2.Software
17.7.2.1.2.1.Information/Data Management Software
17.7.2.1.2.2.Lab Automation Software
17.7.2.1.2.3.Others
17.7.2.1.3.Services
17.7.2.2.Argentina In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
17.7.2.2.1.Immunoassay
17.7.2.2.2.Clinical Chemistry
17.7.2.2.3.Molecular Diagnostics
17.7.2.2.4.Hematology
17.7.2.2.5.Microbiology
17.7.2.2.6.Coagulation
17.7.2.2.7.Others
17.7.2.3.Argentina In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
17.7.2.3.1.Infectious Disease
17.7.2.3.1.1.Hepatitis
17.7.2.3.1.2.Coronavirus Disease (COVID-19)
17.7.2.3.1.3.Others
17.7.2.3.2.Oncology
17.7.2.3.3.Diabetes
17.7.2.3.4.Cardiology
17.7.2.3.5.Gynecology and Women’s Health
17.7.2.3.6.Bone Health
17.7.2.3.7.Autoimmune Diseases
17.7.2.3.8.Others
17.7.2.4.Argentina In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
17.7.2.4.1.Hospitals
17.7.2.4.2.Emergency Care Centers
17.7.2.4.3.Clinical Diagnostics Laboratories
17.7.2.4.4.Academic and Research Institutions
17.7.2.4.5.Home Care
17.7.2.4.6.Others
17.7.2.5.Argentina In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
17.7.2.5.1.Direct
17.7.2.5.2.Indirect
17.7.3.Rest of Latin America
17.7.3.1.Rest of Latin America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Offering
17.7.3.1.1.Products
17.7.3.1.1.1.Systems and Instruments
17.7.3.1.1.1.1.Fully Automated Systems
17.7.3.1.1.1.2.Semi-Automated Systems
17.7.3.1.1.1.3.Others
17.7.3.1.1.2.Assays and Reagents
17.7.3.1.1.3.Calibrators and Control Materials
17.7.3.1.1.4.Reagent Kits
17.7.3.1.1.5.Others
17.7.3.1.2.Software
17.7.3.1.2.1.Information/Data Management Software
17.7.3.1.2.2.Lab Automation Software
17.7.3.1.2.3.Others
17.7.3.1.3.Services
17.7.3.2.Rest of Latin America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Application
17.7.3.2.1.Immunoassay
17.7.3.2.2.Clinical Chemistry
17.7.3.2.3.Molecular Diagnostics
17.7.3.2.4.Hematology
17.7.3.2.5.Microbiology
17.7.3.2.6.Coagulation
17.7.3.2.7.Others
17.7.3.3.Rest of Latin America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Clinical Indication
17.7.3.3.1.Infectious Disease
17.7.3.3.1.1.Hepatitis
17.7.3.3.1.2.Coronavirus Disease (COVID-19)
17.7.3.3.1.3.Others
17.7.3.3.2.Oncology
17.7.3.3.3.Diabetes
17.7.3.3.4.Cardiology
17.7.3.3.5.Gynecology and Women’s Health
17.7.3.3.6.Bone Health
17.7.3.3.7.Autoimmune Diseases
17.7.3.3.8.Others
17.7.3.4.Rest of Latin America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By End Users
17.7.3.4.1.Hospitals
17.7.3.4.2.Emergency Care Centers
17.7.3.4.3.Clinical Diagnostics Laboratories
17.7.3.4.4.Academic and Research Institutions
17.7.3.4.5.Home Care
17.7.3.4.6.Others
17.7.3.5.Rest of Latin America In Vitro Diagnostics (IVD) Market Revenue (US$ Mn) and Forecasts, By Sales Channel
17.7.3.5.1.Direct
17.7.3.5.2.Indirect
17.8.Key Segment for Channeling Investments
17.8.1.By Country
17.8.2.By Offering
17.8.3.By Application
17.8.4.By Clinical Indication
17.8.5.By End Users
17.8.6.By Sales Channel
18.Competitive Benchmarking
18.1.Market Share Analysis, 2022
18.2.Global Presence and Growth Strategies
18.2.1.Mergers and Acquisitions
18.2.2.Product Launches
18.2.3.Investments Trends
18.2.4.R&D Initiatives
19.Player Profiles
19.1.Abbott Laboratories
19.1.1.Company Details
19.1.2.Company Overview
19.1.3.Product Offerings
19.1.4.Key Developments
19.1.5.Financial Analysis
19.1.6.SWOT Analysis
19.1.7.Business Strategies
19.2.BD
19.2.1.Company Details
19.2.2.Company Overview
19.2.3.Product Offerings
19.2.4.Key Developments
19.2.5.Financial Analysis
19.2.6.SWOT Analysis
19.2.7.Business Strategies
19.3.bioMérieux SA
19.3.1.Company Details
19.3.2.Company Overview
19.3.3.Product Offerings